



10041860 081302

#6

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 1

CTAAAAAATATGTTCTCTACAACACCAAGGCTCATTAAAAATATTTTAAATATT
AATATACATTTTCTTCTGTCAGAAATACATAAAACTTTATTATATCAGCGCAGG
GCGGCGCGGCGTCCGTCGGTCCCGGGAGCAGAACCCGGCTTTTTCTTGAGCGACG
CTGTCTCTAGTCGCTGATCCCAAATGCACCGGCTCATCTTTGTCTACACTCTA
ATCTGCGCAAACCTTTTGCAGCTGTCTGGGACACTTCTGCAACCCCGCAGAGCG
CATCCATCAAAGCTTTGCGCAACGCCAACCTCAGGCGAGATGAGAGCAATCA
CCTCACAGACTTGTACCGAAGAGATGAGACCATCCAGGTGAAAGGAAACGG
CTACGTGCAGAGTCCTAGATTCCCGAACAGCTACCCCGAGGAACCTGCTCCTG
ACATGGCGGCTTCACTCTCAGGAGAATACACGGATACAGCTAGTGTTTGACA
ATCAGTTTGATTAGAGGAAGCAGAAAATGATATCTGTAGGTATGATTTTGT
GGAAGTTGAAGATATATCCGAAACCAGTACCATTATTAGAGGACGATGGTGT
GGACACAAGGAAGTTCCCTCCAAGGATAAAATCAAGAACGAACCAAATTTAA
ATCACATTCAAGTCCGATGACTACTTTGTGGCTAAACCTGGATTCAAGATTTA
TTATTCTTTGCTGGAAGATTTCCAACCCGCAGCAGCTTCAGAGACCAACTGGG
AATCTGTCAAGCTCTATTTCAAGGGGTATCCTATAACTCTCCATCAGTAACG
GATCCCACTCTGATTGCGGATGCTCTGGACAAAAAAATTGCAGAATTTGATA
CAGTGGAAGATCTGCTCAAGTACTTCAATCCAGAGTCATGGCAAGAAGATCT
TGAGAATATGTATCTGGACACCCCTCGGTATCGAGGCAGGTCATACCATGAC
CGGAAGTCAAAAGTTGACCTGGATAGGCTCAATGATGATGCCAAGCGTTACA
GTTGCACTCCCAGGAATTACTCGGTCAATATAAGAGAAGAGCTGAAGTTGGC
CAATGTGGTCTTCTTTCCACGTTGCCTCCTCGTGCAGCGCTGTGGAGGAAATT
GTGGCTGTGGAAGTGTCAACTGGAGGTCCTGCACATGCAATTCAGGGAAAAC
CGTGAAAAAGTATCATGAGGTATTACAGTTTGAGCCTGGCCACATCAAGAGG
AGGGGTAGAGCTAAGACCATGGCTCTAGTTGACATCCAGTTGGATCACCATG
AACGATGTGATTGTATCTGCAGCTCAAGACCACCTCGATAAGAGAATGTGCA
CATCCTTACATTAAGCCTGAAAGAACCTTTAGTTTAAGGAGGGTGAGATAAG
AGACCCTTTTCTACCAGCAACCAAACCTTACTACTAGCCTGCAATGCAATGA
ACACAAGTGGTTGCTGAGTCTCAGCCTTGCTTTGTAAATGCCATGGCAAGTAG
AAAGGTATATCATCAACTTCTATACCTAAGAATATAGGATTGCATTTAATAAT
AGTGTGTTGAGGTTATATATGCACAAACACACACAGAAATATATTCATGTCTAT
GTGTATATAGATCAAATGTTTTTTTTGGTATATATAACCAGGTACACCAGAGC
TTACATATGTTTGAGTTAGACTCTTAAATCCTTTGCCAAAATAAGGGATGGT
CAAATATATGAAACATGTCTTTAGAAAATTTAGGAGATAAATTTATTTTAAA
TTTTGAAACACAAAACAATTTTGAATCTTGCTCTCTTAAAGAAAGCATCTTGT
ATATTAAAAATCAAAGATGAGGCTTTCTTACATATACATCTTAGTTG (SEQ
ID NO:50)



10041860 081302

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

Figure 2A

1 CTAAAAAATATGTTCTCTACAACACCAAGGCTCATTAAAAATATTT
46 TAAATATTAATATACATTTTCTTCTGTGTCAGAAATACATAAACTTT
5 91 ATTATATCAGCGCAGGGCGGGCGCGCGTCCGTCCTCCGGGAGCAGAA
136 CCCGGCTTTTCTTGGAGCGACGCTGTCTCTAGTCGCTGATCCCA

181 AATGCACCGGCTCATCTTTGTCTACACTCTAATCTGCGCAAACCTT
MetHisArgLeuIlePheValTyrThrLeuIleCysAlaAsnPhe
10 226 TTGCAGCTGTCCGGACACTTCTGCAACCCCGCAGAGCGCATCCAT
CysSerCysArgAspThrSerAlaThrProGlnSerAlaSerIle

271 CAAAGCTTTGCGCAACGCCAACCTCAGGCGAGATGAGAGCAATCA
15 LysAlaLeuArgAsnAlaAsnLeuArgArgAspGluSerAsnHis

316 CCTCACAGACTTGTACCGAAGAGATGAGACCATCCAGGTGAAAGG
LeuThrAspLeuTyrArgArgAspGluThrIleGlnValLysGly

20 361 AAACGGCTACGTGCAGAGTCCTAGATTCCCGAACAGCTACCCAG
AsnGlyTyrValGlnSerProArgPheProAsnSerTyrProArg

406 GAACCTGCTCCTGACATGGCGGCTTCACTCTCAGGAGAATACAG
AsnLeuLeuLeuThrTrpArgLeuHisSerGlnGluAsnThrArg
25 451 GATACAGCTAGTGTGTTGACAATCAGTTTGGATTAGAGGAAGCAGA
IleGlnLeuValPheAspAsnGlnPheGlyLeuGluGluAlaGlu

496 AAATGATATCTGTAGGTATGATTTTGTGGAAGTTGAAGATATATC
30 AsnAspIleCysArgTyrAspPheValGluValGluAspIleSer

541 CGAAACCAGTACCATTATTAGAAGACGATGGTGTGGACACAAGGA
GluThrSerThrIleIleArgGlyArgTrpCysGlyHisLysGlu

35 586 AGTTCCTCCAAGGATAAAATCAAGAACGAACCAAATTAAATCAC
ValProProArgIleLysSerArgThrAsnGlnIleLysIleThr

631 ATTCAAGTCCGATGACTACTTTGTGGCTAAACCTGGATTCAAGAT



10041860 .081302

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

Figure 2B

PheLysSerAspAspTyrPheValAlaLysProGlyPheLysIle

676 TTATTATTCTTTGCTGGAAGATTTCCAACCCGACGAGCTTCAGA
TyrTyrSerLeuLeuGluAspPheGlnProAlaAlaAlaSerGlu721 GACCAACTGGGAATCTGTCAAGCTCTATTTGAGGGTATCCTA
ThrAsnTrpGluSerValThrSerSerIleSerGlyValSerTyr766 TAACTCTCCATCAGTAACGGATCCCACTCTGATTGCGGATGCTCT
AsnSerProSerValThrAspProThrLeuIleAlaAspAlaLeu811 GGACAAAAAATTGCAGAATTGATACAGTGAAGATCTGCTCAA
AspLysLysIleAlaGluPheAspThrValGluAspLeuLeuLys856 GTACTTCAATCCAGAGTCATGGCAAGAAGATCTTGAGAATATGTA
TyrPheAsnProGluSerTrpGlnGluAspLeuGluAsnMetTyr901 TCTGGACACCCCTCGGTATCGAGGCAGGTCATACCATGACCGGAA
LeuAspThrProArgTyrArgGlyArgSerTyrHisAspArgLys946 GTCAAAAGTTGACCTGGATAGGCTCAATGATGATGCCAAGCGTTA
SerLysValAspLeuAspArgLeuAsnAspAspAlaLysArgTyr991 CAGTTGCACTCCAGGAATTACTCGGTCAATATAAGAGAAGAGCT
SerCysThrProArgAsnTyrSerValAsnIleArgGluGluLeu1036 GAAGTTGGCCAATGTGGTCTTCTTTCCACGTTGCCTCCTCGTGCA
LysLeuAlaAsnValValPhePheProArgCysLeuLeuValGln1081 GCGCTGTGGAGGAAATTGTGGCTGTGGAAGTGTCAACTGGAGGTC
ArgCysGlyGlyAsnCysGlyCysGlyThrValAsnTrpArgSer1126 CTGCACATCAATTGAGGAAAAACCGTGAAAAAGTATCATGAGGT
CysThrCysAsnSerGlyLysThrValLysLysTyrHisGluVal1171 ATTACAGTTTGAGCCTGGCCACATCAAGAGGAGGGGTAGAGCTAA
LeuGlnPheGluProGlyHisIleLysArgArgGlyArgAlaLys



ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF
Corvalan et al.
Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

10041860.061302

Figure 2C

1216 GACCATGGCTCTAGTTGACATCCAGTTGGATCACCATGAACGATG
ThrMetAlaLeuValAspIleGlnLeuAspHisHisGluArgCys

5

1261 TGATTGTATCTGCAGCTCAAGACCACCTCGATAAGAGAATGTGCA
AspCysIleCysSerSerArgProProArg (SEQ ID NO:12)

10

1306 CATCCTTACATTAAGCCTGAAAGAACCTTTAGTTTAAGGAGGGTG
1351 AGATAAGAGACCCCTTTTCCTACCAGCAACCAAACCTTACTACTAGC
1396 CTGCAATGCAATGAACACAAGTGGTTGCTGAGTCTCAGCCTTGCT
1441 TTGTTAATGCCATGGCAAGTAGAAAGGTATATCATCAACTTCTAT
1486 ACCTAAGAATATAGGATTGCATTTAATAATAGTGTTTGAGGTTAT
1531 ATATGCACAAACACACACAGAAATATATTTCATGTCTATGTGTATA
1576 TAGATCAAATGTTTTTTTTTGGTATATATAACCAGGTACACCAGAG
1621 CTTACATATGTTTGGAGTTAGACTCTTAAAATCCTTTGCCAAAATA
15 1666 AGGGATGGTCAAATATATGAAACATGTCTTTAGAAAATTTAGGAG
1711 ATAAATTTATTTTTAAATTTTGAAACACAAAACAATTTGAATCT
1756 TGCTCTCTTAAAGAAAGCATCTTGTATATTAAAAATCAAAGATG
1801 AGGCTTCTTACATATACATCTTAGTTG (SEQ ID NO:50)



10041860 . 091302

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 3

A -- Cur2 1.6 heavy chain nucleotide sequence

GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCCTGGTCAAGCCTGGGGGGTCCC
TGAGACTCTCCTGTGCAGCCTCTGGATTCAACTTCAGAACCTATAACATGAAC
TGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCATCCATTAGTA
GTAGTAGTAGTAACATATACTACGCAGACTCAGTGAAGGGCCGATTACCCAT
CTCCAGAGACAACGCCAAGAACTCACTGTATCTGCAAATGAACAGCCTGAGA
GCCGAGGACACGGCTGTATATTACTGTGCGAGAGATATTATGATTACGTTTG
GGGGAATTATCGCCTCGTTCTACTTTGACTACTGGGGCCAGGGAACCCTGGTC
ACCGTCTCCTCAG (SEQ ID NO:55)

B -- Cur2 1.6 heavy chain amino acid sequence

EVQLVESGGGLVKPGGSLRLSCAASGFNFRITYNMNWVRQAPGKGLEWVSSISS
SSNIYYADSVKGRFTISRDNKNSLYLQMNSLRAEDTAVYYCARDIMITFGGIIAS
FYFDYWGQGLVTVSS (SEQ ID NO:13)

C -- Cur2 1.6 light chain nucleotide sequence

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAG
AGTCACCATCACTTGCCGGGCAAGTCAGGGCATTAGAAATGATTTAGGCTGG
TTTCAGCAGAAACCAGGGAAAGCCCCTAAGCGCCTGATCTATGCTGCATCCA
GTTTGCAAAGTGGGGTCCCATCAAGGTTCAAGCGGCAGTGGATCTGGGACAGA
ATTCATCTCACAAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACT
GTCTACAGCATAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGA
GATCAAAC (SEQ ID NO:56)

D -- Cur2 1.6 light chain amino acid sequence

DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWFQKPGKAPKRLIYAASSLQ
SGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIK (SEQ
ID NO:14)



10041860 .081302

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 4

A -- Cur2 1.11 heavy chain nucleotide sequence

GAGGTGCAGCTGGTGCAGTCTGGAGGAGGCTTGATCCAGCCTGGGGGGTCCC
TGAGACTCTCCTGTGCAGCCTCTGGGTTCACCGTCAGTAGCAACTACATGAGC
TGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGTTATTTATA
GCGGTGGTAGCACATACTACGCAGACTCCGTGAAGGGCCGATTACCATCTC
CAGAGACAATTCCAAGAACACGCTGTATCTTCAAATGAACAGCCTGAGAGCC
GAGGACACGGCCGTGTATTACTGTGCGGGAACGGTGACTACGAATTACTACT
ACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCACCGTCTCCTCAG (SEQ
ID NO:57)

B -- Cur2 1.11 heavy chain amino acid sequence

EVQLVQSGGGLIQPGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSG
GSTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAGTVTTNYYYGM
DVWGQGTTVTVSS (SEQ ID NO:15)

C -- Cur2 1.11 light chain nucleotide sequence

GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCC
GGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTGCAAAGTAATGGATAC
AACTATTTGGATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGA
TCTATTTGGGTTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTTCAGTGGCAGT
GGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATG
TTGGGGTTTATTACTGCATGCAAGCTCTACAACTCTCACTTTCGGCGGAGGG
ACCAAGGTGGAGATCAAAC (SEQ ID NO:58)

D -- Cur2 1.11 light chain amino acid sequence

DIVMTQSPLSLPVTPGEPASISCRSSQSLQSNQYNYLDWYLQKPGQSPQLLIYLG
SNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTLTFGGGTKVEI
K (SEQ ID NO:16)



10041860 .081302

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 5

A -- Cur2 1.17 heavy chain nucleotide sequence

CAGGTGCAGCTGGTGGAGTCGGGGGGAGGCGTGGTCCAGCCTGGGAAGTCCC
TGAGACTCTCCTGTGCAGCGTCTGGATTACCTTCAGTAGCTATGGCATGCAC
TGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGT
ATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTACCAT
CTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGA
GCCGAGGACACGGCTGTGTATTACTGTGCGAGAGATCAAGGATACAGATATG
CTGGTTACTACTACGACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGT
CACCGTCTCCTCAG (SEQ ID NO:59)

B -- Cur2 1.17 heavy chain protein sequence

QVQLVESGGGVVQPGKSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIW
YDGSNKYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARDQGYRYA
GYYYDYGMDVWGQGT TVTVSS (SEQ ID NO:17)

C -- Cur2 1.17 light chain nucleotide sequence

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAG
AGTCACCATCACTTGCCGGGCAAGTCAGGGCATTAGAAATGATTTAGGCTGG
TATCAGCAGAAACCAGGGAAAGCCCCTAAGCGCCTGATCTATGCTGCATCCA
GTTTGCAAAGTGGGGTCCCATCAAGGTTTCAGCGGCAGTGGATCTGGGACAGA
ATTCACTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACT
GTCTACAGCATAATAGTTACCCGCTCACTTTCGGCGGAGGGACCAAGGTGGA
GATCAAAC (SEQ ID NO:60)

D -- Cur2 1.17 light chain protein sequence

DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQ
SGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSYPLTFGGGTKVEIK (SEQ
ID NO:18)



FIGURE 6

A -- Cur2 1.18 heavy chain nucleotide sequence

CAGGTGCAGCTGGTGCAGTCGGGGGCTGAGGTGAAGAAGCCTGGGGCCTCA
GTGAAGGTCTCCTGCAAGGCTTCTGGATACACCTTCACCAGTTATGATATCAA
CTGGGTGCGACAGGCCACTGGACAAGGGCTTGAGTGGATGGGATGGATGAA
CCCAAACAGTGGTAACACAGGCTATGCACAGAAGTTCAGGGCAGAGTCACC
ATGACCAGGAACACCTCCATAAGCACAGCCTACATGGAGCTGAGCAGCCTGA
GATCTGAGGACACGGCCGTGTATTACTGTGCGAGAGAGGGTATAGCAGTGGC
TGGGACATACTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACG
GTCACCGTCTCCTCAG (SEQ ID NO:61)

B -- Cur2 1.18 heavy chain protein sequence

QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWM
NPNSGNTGYAQKFQGRVTMTRNTSISTAYMELSSLRSEDVAVYYCAREGIAVAG
TYYYYYGMVDVWGQGTITVTVSS (SEQ D NO:19)

C -- Cur2 1.18 light chain nucleotide sequence

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAG
AGTCACCATCACTTGCCGGGCAAGTCAGGGCATTAGAAATGATTTAGGCTGG
TATCAGCAGAAACCAGGGAAAGCCCCTAAGCGCCTGATCTATGCTGCATCCA
GTTTGCAAAGTGGGGTCCCATCAAGGTTCAAGCGGCAGTGGATCTGGGACAGA
ATTCATCTCACAAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTTCT
GTCTACAGCATAATAGTTACCCATTCACCTTTCGGCCCTGGGACCAAAGTGGAT
ATCAAAC (SEQ ID NO:62)

D -- Cur2 1.18 light chain protein sequence

DIQMTQSPSSLSASVGDRTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQ
SGVPSRFSGSGSGTEFTLTISLQPEDFATYFCLQHNSYPFTFGPGTKVDIK (SEQ
ID NO:20)



FIGURE 7

A -- Cur2 1.19 heavy chain nucleotide sequence

CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAG
TGAAGGTCTCCTGCAAGGCTTCTGGATACACCTTCACCAGTTATGATATCAAC
TGGGTGCGACAGGCCACTGGACAAGGGCTTGAGTGGATGGGATGGATGAAC
CCTAACAGTGGTAACACAGGCTATGCACAGAAGTTCCAGGGCAGAGTCACCA
TGACCAGGAACACCTCCATAAGCACAGCCTACATGGAGCTGAGCAGCCTGAG
ATCTGAGGACACGGCCGTGTATTACTGTGCGAGAGACGTTATGATTACGTTTG
GGGGAGTTATCGTGCCTACGGTATGGACGTCTGGGGCCAAGGGACCACGGT
CACCGTCTCCTCAG (SEQ ID NO:63)

B -- Cur2 1.19 heavy chain amino acid sequence

QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWM
NPNSGNTGYAQKFQGRVTMTRNTSISTAYMELSSLRSEDVAVYYCARDVMITFG
GVIVHYGMDVWGQGTITVTVSS (SEQ ID NO:21)

C -- Cur2 1.19 light chain nucleotide sequence

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAG
AGTCACCATCACTTGCCGGGCAAGTCAGGGCATTAGAAATGATTTAGGCTGG
TATCAGCAGAAACCAGGGAAAGCCCCTAAGCGCCTGATCTATGCTGCATCCA
GTTTGCAAAGTGGGGTCCCATCAAGGTTTCAGCGGCAGTGGATCTGGGACAGA
TTTCACTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACT
GTCTACAGCATAATAGTGACCCGTGCAGTTTTGGCCAGGGGACCAAGCTGGA
GATCAGAC (SEQ ID NO:64)

D -- Cur2 1.19 light chain amino acid sequence

DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQ
SGVPSRFSGSGSGTDFTLTISLQPEDFATYYCLQHNSDPCSFGQGTKLEIR (SEQ
ID NO:22)



10041860 001302

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 8

A -- Cur2 1.23 heavy chain nucleotide sequence

GAGGTGCAGCTGGTGCAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCT
CTGAAGATCTCCTGTGAGGGTTCTGGATACAGCTTTACCAGCTACTGGATCGG
CTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTAT
CCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCA
TCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAGCAGCCTGAA
GGCCTCGGACACCGCCATGTATTACTGTGCGAGACATGTATCGTATTACTATG
TTTCGGGGAGTTATTATAACGTCTTTGACTACTGGGGCCAGGGAACCCTGGTC
ACCGTCTCCTCAG (SEQ ID NO:65)

B -- Cur2 1.23 heavy chain amino acid sequence

EVQLVQSGAEVKKPGESLKISCEGSGYSFTSYWIGWVRQMPGKGLEWMGIYPG
DSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARHVSYYYVSGS
YYNVFDYWGGQTLVTVSS (SEQ ID NO:23)

C -- Cur2 1.23 light chain nucleotide sequence

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAG
AGTCACCATCACTTGCCGGGCAAGTCAGGGCATTAGAAATGATTTAGGCTGG
TATCAGCAGATACCAGGGAAAGCCCCTAAGCGCCTGATCTATGCTGCATCCA
GTTTGCAACGTGGGGTCCCATCAAGGTTTCAGCGGCAGTGGATCTGGGACAGA
ATTCACTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACT
GTCTACAGCATAATAGTTACCCGTGGACGTTTCGGCCAAGGGACCAAGGTGGA
AATCAAAC (SEQ ID NO:66)

D -- Cur2 1.23 light chain amino acid sequence

DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQIPGKAPKRLIYAASSLQR
GVPSRFSGSGSGTEFTLTISLQPEDFATYYCLQHNSYPWTFGQGKVEIK (SEQ
ID NO:24)



FIGURE 9

A -- Cur2 1.24.1 heavy chain nucleotide sequence

CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCC
TGAGACTCTCCTGTGCAGCGTCTGGATTCAGTTTCAGTAGCTATGGCATGCAC
TGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGATATATGGT
ATGATGGAAGTAATAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCAT
CTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGA
GCCGAGGACACGGCTGTGTATTATTGTGCGAGAGATCAGGGGATACAGCTATG
GTTACGTCTACTACGACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGT
CACCGTCTCCTCAG (SEQ ID NO:67)

B -- Cur2 1.24.1 heavy chain protein sequence

QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQAPGKGLEWVADIW
YDGSNKYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCARDQGYSYG
YVYYDYGMDVWGQGT VTVSS (SEQ ID NO:25)

C -- Cur2 1.24.1 light chain nucleotide sequence

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAG
AGTCACCATCACTTGCCGGGCAAGTCAGGGCATTAGAAATGATTTAGGCTGG
TATCAGCAGAAACCAGGGAAAGCCCCTAAGCGCCTGATCTATGCTGCATCCA
GTTTGCAAAGTGGGGTCCCATCAAGGTTTCAGCGGCAGTGGATCTGGGACAGA
GTTCACTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACT
GTCTACAGCATAATAGTTACCCGTGGACGTTTCGGCCAAGGGACCAAGGTGGA
AATCAAAC (SEQ ID NO:68)

D -- Cur2 1.24.1 light chain protein sequence

DIQMTQSPSSLSASVGRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQ
SGVPSRFSGSGSTEFTLTISSLQPEDFATYYCLQHNSYPWTFGQG TKVEIK (SEQ
ID NO:26)



10041860 .021302

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 10

A -- Cur2 1.25.1 heavy chain nucleotide sequence

GAGGTGCAGCTGGTGCAGTCGGGAGCAGAGGTGAAAAAGCCCGGGGAGTCT
CTGAAGATCTCCTGTAAGGGTTCTGGATACAGGTTTACCAGCTACTGGATCGG
CTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTAT
CCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCA
TCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAGCAGCCTGAA
GGCCTCGGACACCGCCATGTATTACTGTGCGAGACATGGATCGTATTATTATG
GTTCCGGAGACTTATTATAATGTCTTTGACTACTGGGGCCAGGGAACCCTGGTC
ACCGTCTCCTCAG (SEQ ID NO:69)

B -- Cur2 1.25.1 heavy chain protein sequence

EVQLVQSGAEVKKPGESLKISCKGSGYRFTSYWIGWVRQMPGKGLEWMGHIYPG
DSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYCARHGSYYYGSET
YYNVFDYWQGTLTVSS (SEQ ID NO:27)

C -- Cur2 1.25.1 light chain nucleotide sequence

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAG
AGTCACCATCACTTGCCGGGCAAGTCAGGGCATTAGAAATGATTTAGGCTGG
TATCAGCAGAAACCAGGGAAAGCCCCTAAGCGCCTGATCTATGCTGCATCCA
GTTTGCAAAGTGGGGTCCCATCAAGGTTTCAGCGGCAGTGGATCTGGGACAGA
ATTCATCTCACAAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACT
GTCTACAGCATAATAGTTACCCGTGGACGTTTCGGCCAAGGGACCAAGGTGGA
AATCAAAC (SEQ ID NO:70)

D -- Cur2 1.25.1 light chain protein sequence

DIQMTQSPSSLSASVGDRTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQ
SGVPSRFSGSGSGTEFTLTISLQPEDFATYYCLQHNSYPWTFGQGTKVEIK (SEQ
ID NO:28)



FIGURE 11

A -- Cur2 1.29 heavy chain nucleotide sequence

GAGGTGCAGCTGGTGCAGTCGGGAGCAGAGGTGAAAAAGCCCCGGGGAGTCT
CTGAAGATCTCCTGTAAGGGTTCTGGATACAGCTTTACCAGCTACTGGATCGG
CTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTAT
CCTGGTGACTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGCCACCA
TCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAGCAGCCTGAA
GGCCTCGGACACCGCCATGTATTACTGTGCGAGACACGTGGATGTAGGGGCT
ACGATTGGGGGATATTACTATTACTACCACGGTATGGACGTCTGGGGCCAAG
GGACCACGGTCACCGTCTCCTCAG (SEQ ID NO:71)

B -- Cur2 1.29 heavy chain protein sequence

EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIHYPG
DSDTRYSPSFQGGQATISADKSISTAYLQWSSLKASDTAMYCARHVDVGATIGG
YYYYYHGMVDVWGQGTTVTVSS (SEQ ID NO:29)

C -- Cur2 1.29 light chain nucleotide sequence

GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCC
GGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACA
ACTATTTGGATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAACCTCCTGATC
TATTTGGGTTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCACTGGCAGTGG
ATCAGGCACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGACGATGTT
GGGGTTTATTACTGCATGCAAGCTCTACAATCTCTCATGTGCAGTTTGGCCA
GGGGACCAAGCTGGAGATCAAAC (SEQ ID NO:72)

D -- Cur2 1.29 light chain protein sequence

DIVMTQSPLSLPVTPGEPASISCRSSQSLLSNGYNYLDWYLQKPGQSPQLLIYLG
SNRASGVDPDRFSGSGSGTDFTLKISRVEADDVGVYYCMQALQSLMCSFGQGTL
EIK (SEQ ID NO:30)



10041360 .08.1.302

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF
Corvalan et al.
Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 12

A -- Cur2 1.33 heavy chain nucleotide sequence

CAGGTTTCAGCTGGTGCAGTCGGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAG
TGAAGGTCTCCTGCAAGGCTTCTGGTTACACCTTTACCAGCTATGGTATCAGC
TGGGTGCGACAGGCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCG
CTTACAATGGTAACACAACTATGCACAGAAGCTCCAGGGCAGAGTCACCAT
GACCACAGACACATCCACGAGCACAGCCTACATGGAGCTGAGGAGCCTGAG
ATCTGACGACACGGCCGTGTATTACTGTGCGAGAGATCATTACTATGATAGT
AGTGATTATCTCTACTACTACTACGGTTTGGACGTCTGGGGCCAAGGGACCAC
GGTCACCGTCTCCTCAG (SEQ ID NO:73)

B -- Cur2 1.33 heavy chain protein sequence

QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISA
YNGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDHYDSS
DYLYYYYGLDVWGQGTTVTVSS (SEQ ID NO:31)

C -- Cur2 1.33 light chain nucleotide sequence

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAG
AGTCACCATCACTTGCCGGGCGAGTCAGGGCATTAGCAATTATTTAGCCTGGT
ATCAGCAGAAACCAGGGAAAGTTCCTAAGCTCCTGATCTATGCTGCATCCAC
TTTGCAATCAGGGGTCCCATCTCGGTTCAAGTGGCAGTGGATCTGGGACAGATT
TCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTATTACTGT
CAAAAGTATAACAGTGCCCCGCTCACTTTCGGCGGAGGGACCAAGGTGGAGA
TCAAAC (SEQ ID NO:74)

D -- Cur2 1.33 light chain protein sequence

DIQMTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQKPGKVPKLLIYAASLTQ
SGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQKYNAPLTFGGGTKVEIK (SEQ
ID NO:32)



10041860 .061302

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 13

A -- Cur2 1.38.1 heavy chain nucleotide sequence

CAGGTGCAGCTGGTGGAGTCGGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCC
TGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCATGCAC
TGGGTCCGCCAGGCTCCAGGCAAGGGGGCTGGAGTGGGTGGCAATTATATGGT
ATGATGGAAATGATAAATACTATGCAGACTCCGTGAAGGGCCGCTTCACCGT
CTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAGA
GCCGAGGACACGGCTGTGTATTACTGTGCGAGAGGATATTACTATGATAGTA
GTGATTATCTCTACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCAC
GGTCACCGTCTCCTCAG (SEQ ID NO:75)

B -- Cur2 1.38.1 heavy chain protein sequence

QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIIWY
DGNDKYYADSVKGRFTVSRDNSKNTLYLQMNSLRAEDTAVYYCARGYYYDSS
DYLYYYYGMDVWGQGTTTVTVSS (SEQ ID NO:33)

C -- Cur2 1.38.1 light chain nucleotide sequence

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAG
AGTCACCATCACTTGCCGGGCGAGTCAGGGCATTAGCAATTATTTAGCCTGGT
ATCAGCAGAAACCAGGGAAAGTTCCTAACCTCCTGATCTATGCTGCATCCAC
TTTGCAATCAGGGGTCCCATCTCGGTTCAAGTGGCAGTGGATCTGGGACAGATT
TCTCTCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAGCTTATTACTGT
CAAAAGTGTAACAGTGCCCCGTGGACGTTCCGGCCAAGGGACCACGGTGGAG
ATCAAAC (SEQ ID NO:76)

D -- Cur2 1.38.1 light chain protein sequence

DIQMTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQKPGKVPNLLIYAASLTQ
SGVPSRFSGSGTDFSLTISSLQPEDVAAYYCQKCNSAPWTFGQGTTVEIK (SEQ
ID NO:34)



10041860 081302

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 14

A -- Cur2 1.39.1 heavy chain nucleotide sequence

GAGGTGCAGCTGGTGCAGTCGGGAACAGAGGTGAAAAAGCCCGGGGAGTCT
CTGAAGATCTCCTGTAAGGGTTCTGGATACAGGTTTACCAGCTACTGGATCGG
CTGGGTGCGCCAGATGCCCGGGAAAGGCCTGGAGTGGATGGGGATCATCTAT
CCTGGTGA CTCTGATACCAGATACAGCCCGTCCTTCCAAGGCCAGGTCACCA
TCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAGCAGCCTGAA
GGCCTCGGACACCGCCATGTATTACTGTGCGAGACATGGATCGTATTACTATA
ATTCGGGGAGTTATTATAACGTCTTTGACTACTGGGGCCAGGGAACCCTGGTC
ACCGTCTCCTCAG (SEQ ID NO:77)

B -- Cur2 1.39.1 heavy chain protein sequence

EVQLVQSGTEVKKPGESLKISCKGSGYRFTSYWIGWVRQMPGKGLEWMGIHYPG
DSDTRYSPSFQGGQVTISADKSISTAYLQWSSLKASDTAMYYCARHGSYYNNSGS
YYNVFDYWGGQGLTVTVSS (SEQ ID NO:35)

C -- Cur2 1.39.1 light chain nucleotide sequence

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAG
AGTCACCATCACTTGCCGGGCAAGTCAGGGCATTAGAAATGATTTAGGCTGG
TATCAGCAGAAACCAGGGAAAGCCCCCTAAGCGCCTGATCTATGCTGCATCCA
GTTTGCAAAGTGGGGTCCCATCAAGGTTTCAGCGGCAGTGGATCTGGGACAGA
ATTCACTCTCACAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACT
GTCTACAGCATAATAGTTACCCGTGGACGTTTCGGCCAAGGGACCAAGGTGGA
AATCAAAC (SEQ ID NO:78)

D -- Cur2 1.39.1 light chain protein sequence

DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQ
SGVPSRFSGSGSGTEFTLTISLQPEDFATYYCLQHNSYPWTFGQGTKVEIK (SEQ
ID NO:36)



10041860 081302

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 15

A -- Cur2 1.40.1 heavy chain nucleotide sequence

CAGGTGCAGCTGGTGCAGTCGGGGGCTGAGGTGAAGAAGCCTGGGGCCTCA
GTGAAGGTCTCCTGCAAGGCTTCTGGATACACCTTCACCACTTATGATATCAA
CTGGGTGCGACAGGCCACTGGACAAGGGCTTGAGTGGATGGGATGGATGAA
CCCTAACAGTGGTAACACAGGCTATGCACAGAAGTTCCAGGGCAGAGTCACC
ATGACCAGGAACACCTCCCTAAGCACAGCCTACATGGAGCTGAGCAGCCTGA
GATCTGAGGACACGGCCGTGTATTACTGTGCGAGAGATATTGTAGTGGTGGT
AGCTGCTACCAACTACTACAACGGTATGGACGTCTGGGGCCAAGGGACCACG
GTCACCGTCTCCTCAG (SEQ ID NO:79)

B -- Cur2 1.40.1 heavy chain protein sequence

QVQLVQSGAEVKKPGASVKVSCKASGYTFTTYDINWVRQATGQGLEWMGWM
NPNSGNTGYAQKFQGRVTMTRNTSLSTAYMELSSLRSEDVAVYYCARDIVVVV
AATNYNGMDVWGQGTTVTVSS (SEQ ID NO:37)



10041860 081302

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 16

A -- Cur2 1.45 heavy chain nucleotide sequence

CAGGTGCAGCTGGTGCAGTCGGGGGCTGAGGTGAAGAAGCCTGGGGCCTCA
GTGAAGGTCTCCTGCAAGGCTTCTGGATACACCTTCACCAGTTATGATATCAA
CTGGGTGCGACAGGCCACTGGACAAGGGCTTGAGTGGATGGGATGGATGAA
CCCTAACAGTGGTAACACAGGCTATGCACAGAAGTTCCAGGGCAGAGTCACC
ATGACCAGGAACACCTCCATAAGCACAGCCTACATGGAGCTGAGCAGCCTGA
GATCTGAGGACACGGCCGTGTATTACTGTGCGAGAGGCAGTGGATACAGCTA
TGGTTACGACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTC
ACCGTCTCCTCAG (SEQ ID NO:80)

B -- Cur2 1.45 heavy chain protein sequence

QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWM
NPNSGNTGYAQKFQGRVTMTRNTSISTAYMELSSLRSEDVAVYYCARGSGYSYG
YDYYYGMDVWGQGTITVTVSS (SEQ ID NO:38)

C -- Cur2 1.45 light chain nucleotide sequence

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAG
AGTCACCATCAATTGCCGGGCGAGTCAGGGCATTAGCAATGATTTAGCCTGG
TATCAGCAGAAACCAGGGAAAGTTCCTAAGCTCCTGATCTATGCTGCATCCA
CTTTGCAATTAGGGGTCCCATCTCGGTTCAAGTGGCAGTGGATCTGGGACAGAT
TTCATCTCACCATCAGCAGCCTGCAGCCTGAAGATGTTGCAACTTATTACTG
TCAAAAGTATAACAGTGCCCCATTCACTTTCGGCCCTGGGACCAAAGTGGAT
ATCAAAC (SEQ ID NO:81)

D -- Cur2 1.45 light chain protein sequence

DIQMTQSPSSLSASVGDRVTINCRASQGISNDLAWYQQKPGKVPKLLIYAASLTQ
LGVPSRFSGSGSGTDFLTISLQPEDVATYYCQKYNAPFTFGPGTKVDIK (SEQ
ID NO:39)



FIGURE 17

A -- Cur2 1.46.1 heavy chain nucleotide sequence

CAGGTGCAGCTGGTGCAGTCGGGGGCTGAGGTGAAGAAGCCTGGGGCCTCA
GTGAAGGTCTCCTGCAAGGCTTCTGGATACTCCTTCACCAGTTATGATATCAA
CTGGGTGCGACAGGCCACTGGACAAGGGCTTGAGTGGATGGGATGGATGAA
CCCTAACAATGGTAACACAGGCTATGCACAGAAGTCCAGGGCAGAGTCACC
ATGACCAGGAACACCTCCATAAGCACAGCCTACATGGAGCTGAGCAGCCTGA
GATCTGAGGACACGGCCGTGTATTACTGTGCGAGAGATATTGTAGTGGTGGT
AACTGCTACGGACTACTACTACGGTATGGACGTCTGGGGCCAAGGGACCACG
GTCACCGTCTCCTCAG (SEQ ID NO:82)

B -- Cur2 1.46.1 heavy chain protein sequence

QVQLVQSGAEVKKPGASVKVSKASGYSFTSYDINWVRQATGQGLEWMGWM
NPNNGNTGYAQKFQGRVTMTRNTSISTAYMELSSLRSEDVAVYYCARDIVVVVT
ATDYYYGMDVWGQGTITVTVSS (SEQ ID NO:40)

C -- Cur2 1.46.1 light chain nucleotide sequence

GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAG
AGTCACCATCACTTGCCGGGCAAGTCAGGGCATTAGAAATGATTTAGGCTGG
TATCAGCAGAAACCAGGGAAAGCCCCCTAAGCGCCTGATTTTTGCTGCATCCA
GTTTGCCAAGTGGGGTCCCATCAAGGTTCAAGCGGAGTGGATCTGGGACAGA
ATTCATCTCACAAATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACT
GTCTACAGCATAGTGGTTACCCTCCGACGTTCCGGCCAAGGGACCAAGGTGGA
AATCAAAC (SEQ ID NO:83)

D -- Cur2 1.46.1 light chain protein sequence

DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIFAASSLPS
GVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHSGYPPTFGQGTKVEIK (SEQ ID
NO:41)



10041860 .081302

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 18

A -- Cur2 1.48.1 heavy chain nucleotide sequence

CAGGTTTCAGCTGGTGCAGTCGGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAG
TGAAGGTCTCCTGCAAGGCTTCTGGTTACACCTTTACCAGCTATGGTATCAGC
TGGGTGCGACAGGCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAGCG
CTTACAATGGTAACACAACTATGCACAGAAGCTCCAGGGCAGAGTCACCAT
GACCACAGACACATCCACGAGCACAGCCTACATGGAGCTGAGGAGCCTGAG
ATCTGACGACACGGCCGTGTATTACTGTGCGAGAGATGTTGAATATTACTATG
ATGGTAGTGGTTATTACTACTTTGACTACTGGGGCCAGGGAACCCTGGTCACC
GTCTCCTCAG (SEQ ID NO:84)

B -- Cur2 1.48.1 heavy chain protein sequence

QVQLVQSGAEVKKPGASVKVSKASGYTFTSYGISWVRQAPGQGLEWMGWISA
YNGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDVEYYD
GSGYYYFDYWGQGLTVTVSS (SEQ ID NO:42)

C -- Cur2 1.48.1 light chain nucleotide sequence

GACATCCAGATGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAG
AGTCACCATCACTTGTCGGGCGAGTCAGGGTATTAGCAGCTGGTTAGCCTGG
TATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCA
TTTTGCAAAGTGGGGTCCCATCAAGGTTCAAGCGGCAGTGGATCTGGGACAGA
TTTCACTCTCACCATCAGCAGCCTGCAGCCTGAGGATTTTGCATCTTACTATT
GTCAACAGTCTAACAGTTTCCCTCGGACGTTTCGGCCAAGGGACCAAGGTGGA
GATCAAAC (SEQ ID NO:85)

D -- Cur2 1.48.1 light chain protein sequence

DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQKPGKAPKLLIYAASILQ
SGVPSRFSGSGSDFTLTISLQPEDFASYCQQSNSFPRTFGQGTKVEIK (SEQ
ID NO:43)



10041860 .081302

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 19

A -- Cur2 1.49.1 heavy chain nucleotide sequence

CAGGTGCAGCTGGTGCAGTCGGGGGCTGAGGTGAAGAAGCCTGGGGCCTCA
GTGAAGGTCTCCTGCAAGGCTTCTGGATACACCTTCACCAGTTATGATATCAA
CTGGGTGCGACAGGCCACTGGACAAGGGCTTGAGTGGATGGGATGGATGAA
CCCTAACAGTGGTGACACAGGCTATGCACAGAAGTTCAGGGCAGAGTCACC
ATGACCAGGAACACCTCCATAAGCACAGCCTACATGGAGCTGAGCAGCCTGA
GATCTGAGGACACGGCCGTGTATTTCTGTGCGAGAATGAGGGATATAGTGGC
TACGAGCTATTACTACTACTTCTACGGTATGGACGTCTGGGGCCAAGGGACC
ACGGTCACCGTCTCCTCAG (SEQ ID NO:86)

B -- Cur2 1.49.1 heavy chain protein sequence

QVQLVQSGAEVKKPGASVKVSKASGYTFTSYDINWVRQATGQGLEWMGWM
NPNSGDTGYAQKFQGRVTMTRNTSISTAYMELSSLRSEDNAVYFCARMRDIVAT
SYYYFYGMVWVGQGTITVTVSS (SEQ ID NO:44)

C -- Cur2 1.49.1 light chain nucleotide sequence

GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCC
GGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACA
ACTATTTGGATTGGTACCTGCTGAAGCCAGGGCAGTCTCCACAGCTCCTGATC
TATTTGGGTTCTAGTCGGGCCTCCGGGGTCCCTGACAGGTTTCAAGTGGCAGTGG
ATCAGGCACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTT
GGGGTTTATTACTGCATGCAAACCTCTACAACTATCACCTTCGGCCAAGGGA
CACGACTGGAGATTAAAC (SEQ ID NO:87)

D -- Cur2 1.49.1 light chain protein sequence

DIVMTQSPLSLPVTPGEPASISCRSSQSLHLSNGYNYLDWYLLKPGQSPQLLIYLG
SSRASGVPRFSGSGSDFTLKISRVEAEDVGVYYCMQTLQTITFGQGRLEIK
(SEQ ID NO:45)



10041860 .081302

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 20

A -- Cur2 1.51 heavy chain nucleotide sequence

GAGGTGCAGCTGGTGCAGTCGGGAGCTGAGGTGAAAAAGCCCCGGGGAGTCT
CTGAAGATCTCCTGTAAGGGTTCTGGATACAGCTTTACCAGCTACTGGATCGG
CTGGGTGCGCCAGATGCCCGGGAAGGCCTGGAGTGGATGGGGATCATCTAT
CCTGGTGA CTCTGATGCCAAATACAGCCCGTCCTTCCAAGGCCAGGTCACCA
TCTCAGCCGACAAGTCCATCAGCACCGCCTACCTGCAGTGGAGCAGCCTGAA
GGCCTCGGACACCGCCATGTATTACTGTGCGAGACACTATGATTACGTTTGGA
GGAATTATCGGTATACAGGGTGGTTCGACCCCTGGGGCCAGGGAACCCTGGT
CACCGTCTCCTCAG (SEQ ID NO:88)

B -- Cur2 1.51.1 heavy chain protein sequence

EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIYPG
DSDAKYSPSFQGGQVTISADKSISTAYLQWSSLKASDTAMYYCARHYDYVWRNY
RYTGWFDPWGQGTLVTVSS (SEQ ID NO:46)

C -- Cur2 1.51.1 light chain nucleotide sequence

GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAG
AGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCC
TGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCAT
CCAACAGGGCCACTGGCATCCCAGACAGGTTTCAGTGGCAGTGGGTCTGGGAC
AGACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATT
ACTGTCAGCAGTATGGTAGCTCACTATTCACTTTCGGCCCTGGGACCAAAGTG
GATATCAAAC (SEQ ID NO:89)

D -- Cur2 1.51.1 light chain protein sequence

EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASNRA
TGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSLFTFGPGTKVDIK (SEQ
ID NO:47)



10041860 .081302

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 21

A -- Cur2 6.4 heavy chain nucleotide sequence

CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAG
TGAAGGTCTCCTGCAAGGCTTCTGGATACACCTTCACCAGTTATGATATCAAC
TGGGTGCGACAGGCCACTGGACAAGGGCTTGAGTGGATGGGATGGATAAAC
CCTAATAGTGGTAACACAGACTATGCACAGAAGTTCCAGGGCAGAGTCACCA
TGACCAGGGACACCTCCATAAGCACAGCCTACATGGAGCTGAGCAGCCTGAG
ATCTGAGGACACGGCCATATATTATTGTGTGAGAGGCTTTGGATACAGCTAT
AATTACGACTACTATTACGGTATGGACGTCTGGGGCCAAGGGACCACGGTCA
CCGTCTCCTCAGT (SEQ ID NO:90)

B -- Cur2 6.4 heavy chain amino acid sequence

QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWIN
PNSGNTDYAQKFQGRVTMTRDTSISTAYMELSSLRSEDTAIYYCVRGFGYSYNY
DYYYGMDVWGQGTITVTVSS (SEQ ID NO:48)

C -- Cur2 6.4 light chain nucleotide sequence

GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAG
AGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGTAGTAGTTACTTAGCCT
GGTACCAGCAGAAGCCTGGCCAGGCTCCCAGGCTCCTCATCTATGCTACATC
CAGCAGGGCCACTGGCATCCCAGACAGGTTTCAGTGGCAGTGGGTCTGGGACA
GACTTCACTCTCACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTA
CTGTCAGCAGTATGGTAGTTCACCGTGCAGTTTGGCCAGGGGACCAAGCTG
GAAATCAAGC (SEQ ID NO:91)

D -- Cur2 6.4 light chain amino acid sequence

EIVLTQSPGTLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYATSSRA
TGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPCSFQGQGTKLEIK (SEQ
ID NO:49)



10041860 081302

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 22A

Clone	Germline genes used				No. of Nucleotide/ Amino acid changes						
					FR1	CDR1	FR2	CDR2	FR3	CDR3	FR4
CR2		V	D	J	V					D & J	
1.19.1	VH	V1-8	D3-16	JH6B	0/0	0/0	0/0	0/0	0/0	0/0	0/0
	VK	A30		JK2	0/0	0/0	0/0	0/0	1/1	1/1	0/0
6.4.1	VH	V1-8	D5-18	JH6B	0/0	0/0	0/0	3/2	5/3	0/0	0/0
	VK	A27		JK2	0/0	3/0	1/0	2/2	0/0	1/0	0/0
1.18	VH	V1-8	D6-19	JH6B	1/0	0/0	0/0	1/0	0/0	0/0	0/0
	VK	A30		JK3	0/0	0/0	0/0	0/0	1/1	0/0	0/0
1.40.1	VH	V1-8	D2	JH6B	1/0	1/1	0/0	0/0	1/1	0/0	0/0
	VK	mix									
1.45	VH	V1-8	DK4	JH6B	1/0	0/0	0/0	0/0	0/0	0/0	0/0
	VK	A20		JK3	1/1	1/1	0/0	1/1	0/0	0/0	0/0
1.46.1	VH	V1-8	D2	JH6B	1/0	1/1	0/0	0/0	1/1	0/0	0/0
	VK	A30		JK1	0/0	0/0	2/1	1/1	0/0	2/2	0/0
1.49.1	VH	V1-8	D5-12	JH6B	1/0	0/0	0/0	1/1	1/1	0/0	0/0
	VK	A19		JK5	0/0	0/0	1/1	1/1	0/0	1/1	0/0
1.33	VH	V1-18	D21-9	JH6B	1/0	0/0	0/0	0/0	0/0	0/0	0/0
	VK	A20		JK4	0/0	0/0	0/0	0/0	0/0	0/0	0/0
1.48.1	VH	V1-18	D21-9	JH4B	1/0	0/0	0/0	0/0	0/0	0/0	0/0
	VK	L5		JK1	0/0	0/0	0/0	1/1	2/1	1/1	0/0
1.6.1	VH	V3-21	D3-16	JH4B	0/0	4/4	0/0	1/1	1/0	0/0	0/0
	VK	A30		JK4	0/0	0/0	1/1	0/0	0/0	0/0	0/0
1.17.1	VH	V3-33	D5-18	JH6B	2/1	0/0	0/0	0/0	0/0	0/0	0/0
	VK	A30		JK4	0/0	0/0	0/0	0/0	0/0	0/0	0/0
1.24.1	VH	V3-33	D5-18	JH6B	0/0	2/1	0/0	1/1	0/0	0/0	0/0
	VK	A30		JK1	0/0	0/0	0/0	0/0	1/0	0/0	0/0
1.38.1	VH	V3-33	D21-9	JH6B	1/0	0/0	0/0	3/3	2/1	0/0	0/0
	VK	A20		JK1	0/0	0/0	1/1	0/0	2/2	1/1	0/0
1.11.1	VH	V3-53	D4-17	JH6B	0/0	0/0	0/0	0/0	0/0	0/0	0/0
	VK	A19		JK4	0/0	1/1	0/0	0/0	0/0	0/0	0/0
1.23.1	VH	V5-51	D3-10	JH4B	1/1	0/0	0/0	0/0	0/0	0/0	0/0
	VK	A30		JK1	0/0	0/0	1/1	1/1	0/0	0/0	0/0
1.25.1	VH	V5-51	D3-10	JH4B	1/0	1/1	0/0	0/0	0/0	0/0	0/0
	VK	A30		JK1	0/0	0/0	0/0	0/0	0/0	0/0	0/0
1.29	VH	V5-51	D5-12	JH6B	1/0	0/0	0/0	0/0	1/1	0/0	0/0
	VK	A19		JK2	0/0	0/0	1/0	0/0	1/1	0/0	0/0
1.39.1	VH	V5-51	D3-10	JH4B	2/1	1/1	0/0	0/0	0/0	0/0	0/0
	VK	A30		JK1	0/0	0/0	0/0	0/0	0/0	0/0	0/0
1.51.1	VH	5-51	D3-16	JH5B	2/0	0/0	0/0	1/1	1/1	0/0	0/0
	VK	A27		JK3	0/0	0/0	0/0	1/1	0/0	0/0	0/0



10041860 .001302

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 22B

Clone	Germline genes used				No. of Nucleotide/ Amino acid changes						
					FR1	CDR1	FR2	CDR2	FR3	CDR3	FR4
CR2		V	D	J	V					D & J	
1.40.1	VH	V1-8	D2	JH6B	1/0	1/1	0/0	0/0	1/1	0/0	0/0
	VK	mix									
1.48.1	VH	V1-18	D21-9	JH4B	1/0	0/0	0/0	0/0	0/0	0/0	0/0
	VK	L5		JK1	0/0	0/0	0/0	1/1	2/1	1/1	0/0
1.49.1	VH	V1-8	D5-12	JH6B	1/0	0/0	0/0	1/1	1/1	0/0	0/0
	VK	A19		JK5	0/0	0/0	1/1	1/1	0/0	1/1	0/0
1.11.1	VH	V3-53	D4-17	JH6B	0/0	0/0	0/0	0/0	0/0	0/0	0/0
	VK	A19		JK4	0/0	1/1	0/0	0/0	0/0	0/0	0/0
1.29	VH	V5-51	D5-12	JH6B	1/0	0/0	0/0	0/0	1/1	0/0	0/0
	VK	A19		JK2	0/0	0/0	1/0	0/0	1/1	0/0	0/0
1.45	VH	V1-8	DK4	JH6B	1/0	0/0	0/0	0/0	0/0	0/0	0/0
	VK	A20		JK3	1/1	1/1	0/0	1/1	0/0	0/0	0/0
1.33	VH	V1-18	D21-9	JH6B	1/0	0/0	0/0	0/0	0/0	0/0	0/0
	VK	A20		JK4	0/0	0/0	0/0	0/0	0/0	0/0	0/0
1.38.1	VH	V3-33	D21-9	JH6B	1/0	0/0	0/0	3/3	2/1	0/0	0/0
	VK	A20		JK1	0/0	0/0	1/1	0/0	2/2	1/1	0/0
6.4.1	VH	V1-8	D5-18	JH6B	0/0	0/0	0/0	3/2	5/3	0/0	0/0
	VK	A27		JK2	0/0	3/0	1/0	2/2	0/0	1/0	0/0
1.51.1	VH	5-51	D3-16	JH5B	2/0	0/0	0/0	1/1	1/1	0/0	0/0
	VK	A27		JK3	0/0	0/0	0/0	1/1	0/0	0/0	0/0
1.19.1	VH	V1-8	D3-16	JH6B	0/0	0/0	0/0	0/0	0/0	0/0	0/0
	VK	A30		JK2	0/0	0/0	0/0	0/0	1/1	1/1	0/0
1.18	VH	V1-8	D6-19	JH6B	1/0	0/0	0/0	1/0	0/0	0/0	0/0
	VK	A30		JK3	0/0	0/0	0/0	0/0	1/1	0/0	0/0
1.6.1	VH	V3-21	D3-16	JH4B	0/0	4/4	0/0	1/1	1/0	0/0	0/0
	VK	A30		JK4	0/0	0/0	1/1	0/0	0/0	0/0	0/0
1.23.1	VH	V5-51	D3-10	JH4B	1/1	0/0	0/0	0/0	0/0	0/0	0/0
	VK	A30		JK1	0/0	0/0	1/1	1/1	0/0	0/0	0/0
1.25.1	VH	V5-51	D3-10	JH4B	1/0	1/1	0/0	0/0	0/0	0/0	0/0
	VK	A30		JK1	0/0	0/0	0/0	0/0	0/0	0/0	0/0
1.39.1	VH	V5-51	D3-10	JH4B	2/1	1/1	0/0	0/0	0/0	0/0	0/0
	VK	A30		JK1	0/0	0/0	0/0	0/0	0/0	0/0	0/0
1.17.1	VH	V3-33	D5-18	JH6B	2/1	0/0	0/0	0/0	0/0	0/0	0/0
	VK	A30		JK4	0/0	0/0	0/0	0/0	0/0	0/0	0/0
1.24.1	VH	V3-33	D5-18	JH6B	0/0	2/1	0/0	1/1	0/0	0/0	0/0
	VK	A30		JK1	0/0	0/0	0/0	0/0	1/0	0/0	0/0
1.46.1	VH	V1-8	D2	JH6B	1/0	1/1	0/0	0/0	1/1	0/0	0/0
	VK	A30		JK1	0/0	0/0	2/1	1/1	0/0	2/2	0/0



10041860.081302

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860. Atty Docket: ABGENIX.051A

FIGURE 23**Figure 23A**

								Section 1
	(1)	1	10	20	30	40	51	
CUR2-1.6.1_HC	(1)	EVQLVESGGGLVQPGGSLRLSCAASGFTNFR						YNNMNVROAPGKGLEWVSSI
VH3-21	(1)	EVQLVESGGGLVQPGGSLRLSCAASGFTFS						YSNMNVROAPGKGLEWVSSI
Consensus	(1)	EVQLVESGGGLVQPGGSLRLSCAASGF						F SY MNWVRQAPGKGLEWVSSI
								Section 2
	(52)	52	60	70	80	90	102	
CUR2-1.6.1_HC	(52)	SSSSSNIIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARDIMI						
VH3-21	(52)	SSSSSVIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAR----						
Consensus	(52)	SSSSS IYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCAR						
								Section 3
	(103)	103	110	126				
CUR2-1.6.1_HC	(103)	TFGGIIASFYFDYWGQGLTVTVSS						
VH3-21	(99)	-----						
Consensus	(103)							

Figure 23B

								Section 1	
	(1)	1	10	20	30	40	51		
CUR2-1.6.1_LC	(1)	DIQMTQSPSSLSASVGDRVTITCRASQGIKNDLGV					QOKPGKAPKRLIYAA		
A30	(1)	DIQMTQSPSSLSASVGDRVTITCRASQGIKNDLGV					QOKPGKAPKRLIYAA		
Consensus	(1)	DIQMTQSPSSLSASVGDRVTITCRASQGIKNDLGV					QOKPGKAPKRLIYAA		
								Section 2	
	(52)	52	60	70	80	90	102		
CUR2-1.6.1_LC	(52)	SSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLOHNSYP						PLTFGGGT	
A30	(52)	SSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLOHNSYP						-----	
Consensus	(52)	SSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLOHNSYP							
								Section 3	
	(103)	103	107						
CUR2-1.6.1_LC	(103)	KVEIK							
A30	(96)	-----							
Consensus	(103)								



FIGURE 24

Figure 24A

						Section 1
	(1)	1	10	20	30	40 51
Cur2-1.11.1_HC	(1)	EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVI				
VH3-53	(1)	EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVI				
Consensus	(1)	EVQLVESGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVI				
						Section 2
	(52)	52	60	70	80	90 102
Cur2-1.11.1_HC	(52)	YSGGSTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAGTVTTN				
VH3-53	(52)	YSGGSTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCAR-----				
Consensus	(52)	YSGGSTYYADSVKGRFTISRDN SKNTLYLQMNSLRAEDTAVYYCA				
						Section 3
	(103)	103	110	120		
Cur2-1.11.1_HC	(103)	YYYGMDVWGQGTTVTVSS				
VH3-53	(98)	-----				
Consensus	(103)					

Figure 24B

		Section 1							
		(1) 1	10	20	30	40 51			
CUR2-1.11.1_LC	(1)	DIVMTQSPFLSLPVTPGEPASISCRSSQSLLQSN GYN YLDWY LQKPGQSPQL							
A19	(1)	DIVMTQSPFLSLPVTPGEPASISCRSSQSLLH SGN YN YLDWY LQKPGQSPQL							
Consensus	(1)	DIVMTQSPFLSLPVTPGEPASISCRSSQSLL SGN YN YLDWY LQKPGQSPQL							
		Section 2							
		(52) 52	60	70	80	90 102			
CUR2-1.11.1_LC	(52)	LIYLGSNRASGVPDFRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTLP							
A19	(52)	LIYLGSNRASGVPDFRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTP--							
Consensus	(52)	LIYLGSNRASGVPDFRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQT							
		Section 3							
		(103) 103	111						
CUR2-1.11.1_LC	(103)	GGGTRVEIK							
A19	(101)	-----							
Consensus	(103)								



10041860 . 081302
ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 25

Figure 25A

Section 1					
	(1)	10	20	30	40
CR2-1.17.1 HC	(1)	QVQLVESGGGVVQPG	SLRLSCAASGFTFSSYGMHWVROAPGKGLEWVAVI		51
VH3-33	(1)	QVQLVESGGGVVQPG	SLRLSCAASGFTFSSYGMHWVROAPGKGLEWVAVI		
Consensus	(1)	QVQLVESGGGVVQPGKSLRLSCAASGFTFSSYGMHWVROAPGKGLEWVAVI			
Section 2					
	(52)	60	70	80	90
CR2-1.17.1 HC	(52)	WYDGSNKYYADSVKGRFTISRDN SKNTLYLQMN SLRAEDTAVYYCARDQGY			102
VH3-33	(52)	WYDGSNKYYADSVKGRFTISRDN SKNTLYLQMN SLRAEDTAVYYCAR----			
Consensus	(52)	WYDGSNKYYADSVKGRFTISRDN SKNTLYLQMN SLRAEDTAVYYCAR			
Section 3					
	(103)	110	126		
CR2-1.17.1 HC	(103)	RYAGYYYDYGMDVWGQGTTVTVSS			
VH3-33	(99)	-----			
Consensus	(103)				

Figure 25B

Section 1					
	(1)	10	20	30	40
CR2-1.17.1 LC	(1)	DIQMTQSPSSLSASVGDRVTITCRASQGI RNDLGWYQQKPGKAPKRLIYAAS			52
A30	(1)	DIQMTQSPSSLSASVGDRVTITCRASQGI RNDLGWYQQKPGKAPKRLIYAAS			
Consensus	(1)	DIQMTQSPSSLSASVGDRVTITCRASQGI RNDLGWYQQKPGKAPKRLIYAAS			
Section 2					
	(53)	60	70	80	90
CR2-1.17.1 LC	(53)	SLQSGVPSRFSGSGSGTEFTLTIS SLQPEDPATYYCLQHN SYP			104
A30	(53)	SLQSGVPSRFSGSGSGTEFTLTIS SLQPEDPATYYCLQHN SYP-----			
Consensus	(53)	SLQSGVPSRFSGSGSGTEFTLTIS SLQPEDPATYYCLQHN SYP			
Section 3					
	(105)	1067			
CR2-1.17.1 LC	(105)	EIK			
A30	(96)	---			
Consensus	(105)				



10041860 081302

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 26**Figure 26A**

								Section 1
	(1)	1	10	20	30	40	52	
CR2-1.18_HC	(1)	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMN						
VH1-8	(1)	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMN						
Consensus	(1)	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWMN						
								Section 2
	(53)	53	60	70	80	90	104	
CR2-1.18_HC	(53)	PNSGNTGYAQKFGQGRVTMTNTSISTAYMELSSLRSEDTAVYYCAREGIAVA						
VH1-8	(53)	PNSGNTGYAQKFGQGRVTMTNTSISTAYMELSSLRSEDTAVYYCAR-----						
Consensus	(53)	PNSGNTGYAQKFGQGRVTMTNTSISTAYMELSSLRSEDTAVYYCAR						
								Section 3
	(105)	105	110	126				
CR2-1.18_HC	(105)	GTYYYYYGMDVWGQGTTVTVSS						
VH1-8	(99)	-----						
Consensus	(105)							

Figure 26B

								Section 1	
	(1)	1	10	20	30	40	53		
CR2-1.18_LC	(1)	DIQMTQSPFSSLSASVGDRTTTCRASQGIKNDLGWYQOKPGKAPKRLIYAASS							
A30	(1)	DIQMTQSPFSSLSASVGDRTTTCRASQGIKNDLGWYQOKPGKAPKRLIYAASS							
Consensus	(1)	DIQMTQSPFSSLSASVGDRTTTCRASQGIKNDLGWYQOKPGKAPKRLIYAASS							
								Section 2	
	(54)	54	60	70	80	90	106		
CR2-1.18_LC	(54)	LQSGVPRFRFSGSGSGTEFTLTISSLQPEDFATYFCLOHNSYPFTFGPGTKVDI							
A30	(54)	LQSGVPRFRFSGSGSGTEFTLTISSLQPEDFATYFCLOHNSYP-----							
Consensus	(54)	LQSGVPRFRFSGSGSGTEFTLTISSLQPEDFATYFCLOHNSYP							
								Section 3	
	(107)	107							
CR2-1.18_LC	(107)	K							
A30	(96)	-							
Consensus	(107)								



10041860 081302

ANTIBODIES DIRECTED TO PDGFR AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 27

Figure 27A

								Section 1
	(1)	1	10	20	30	40	52	
Cur2-1.19.1_hc	(1)	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVROATGQGLEWMGWMN						
VH1-8	(1)	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVROATGQGLEWMGWMN						
Consensus	(1)	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVROATGQGLEWMGWMN						
								Section 2
	(53)	53	60	70	80	90	104	
Cur2-1.19.1_hc	(53)	PNSGNTGYAQKPGQGVMTMTRNTSISTAYMELSSLRSEDVAVYYCARDVMTF						
VH1-8	(53)	PNSGNTGYAQKPGQGVMTMTRNTSISTAYMELSSLRSEDVAVYYCAR-----						
Consensus	(53)	PNSGNTGYAQKPGQGVMTMTRNTSISTAYMELSSLRSEDVAVYYCAR						
								Section 3
	(105)	105	110	126				
Cur2-1.19.1_hc	(105)	GGVIVHYGMDVWGQGTITVTVSS						
VH1-8	(99)	-----						
Consensus	(105)							

Figure 27B

								Section 1
	(1)	1	10	20	30	40	52	
Cur2-1.19.1_lc	(1)	DIQMTQSPSSLSASVGDRVTITCRASQGIKNDLGWYQKPGKAPKRLIYAAS						
A30	(1)	DIQMTQSPSSLSASVGDRVTITCRASQGIKNDLGWYQKPGKAPKRLIYAAS						
Consensus	(1)	DIQMTQSPSSLSASVGDRVTITCRASQGIKNDLGWYQKPGKAPKRLIYAAS						
								Section 2
	(53)	53	60	70	80	90	104	
Cur2-1.19.1_lc	(53)	SLQSGVPSRFSGSGSGTFTLTISISLQPEDFATYYCLOHNSDPCSFQGGTKL						
A30	(53)	SLQSGVPSRFSGSGSGTFTLTISLQPEDFATYYCLOHNSYP-----						
Consensus	(53)	SLQSGVPSRFSGSGSGTDFTLTISISLQPEDFATYYCLOHNS P						
								Section 3
	(105)	<u>1067</u>						
Cur2-1.19.1_lc	(105)	EIR						
A30	(96)	---						
Consensus	(105)							



10041860 . 081302

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 28**Figure 28A**

						Section 1		
	(1)	1	10	20	30	40	51	
Cur2-1.23.1_HC	(1)	EVQLVQSGAEVKKRQEGESLKISCEGSGYSFTSYWIGWVRQMPGKGLEWMGII						
VH5-51	(1)	EVQLVQSGAEVKKRQEGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGII						
Consensus	(1)	EVQLVQSGAEVKKRQEGESLKISC GSGYSFTSYWIGWVRQMPGKGLEWMGII						
						Section 2		
	(52)	52	60	70	80	90	102	
Cur2-1.23.1_HC	(52)	YPGDSDTRYSPSFQSGQVTISADKSIISTAYLQWSSSLKASDTAMYYCARHVS						
VH5-51	(52)	YPGDSDTRYSPSFQSGQVTISADKSIISTAYLQWSSSLKASDTAMYYCAR----						
Consensus	(52)	YPGDSDTRYSPSFQSGQVTISADKSIISTAYLQWSSSLKASDTAMYYCAR						
						Section 3		
	(103)	103	110	126				
Cur2-1.23.1_HC	(103)	YYVSGSYYNVFDYWGGQGLTVTVSS						
VH5-51	(99)	-----						
Consensus (103)								

Figure 28B

						Section 1
	(1)	1	10	20	30	40 51
Cur2-1.23.1_LC	(1)	DIQMTQSPSSLSASVGDRTITCRASQGIKNDLGWYQQIFGKAPKRLIYAA				
A30	(1)	DIQMTQSPSSLSASVGDRTITCRASQGIKNDLGWYQQKPGKAPKRLIYAA				
Consensus	(1)	DIQMTQSPSSLSASVGDRTITCRASQGIKNDLGWYQQ PGKAPKRLIYAA				
						Section 2
	(52)	52	60	70	80	90 102
Cur2-1.23.1_LC	(52)	SSLQRGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLOHNSYPWTFGQGT				
A30	(52)	SSLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLOHNSYP-----				
Consensus	(52)	SSLQ GVPSPRFSGSGSGTEFTLTISSLQPEDFATYYCLOHNSYP				
						Section 3
	(103)	103 107				
Cur2-1.23.1_LC	(103)	KVEIK				
A30	(96)	-----				
Consensus	(103)					



10041860.081302

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 29**Figure 29A**

								Section 1	
	(1)	1	10	20	30	40	51		
CR2-1.24.1_HC	(1)	QVQLVESGGGVVQPGRSLRLSCAASGFFPSSTGMHWVRQAPGKGLEWVADI							
VH3-33	(1)	QVQLVESGGGVVQPGRSLRLSCAASGFFPSSTGMHWVRQAPGKGLEWVAVI							
Consensus	(1)	QVQLVESGGGVVQPGRSLRLSCAASGFSFSSYGMHWVRQAPGKGLEWVA I							
								Section 2	
	(52)	52	60	70	80	90	102		
CR2-1.24.1_HC	(52)	WYDGSNKYYADSVKGRFTISRDNBKNLTLYLQMNSLRAEDTAVYYCARDQGY							
VH3-33	(52)	WYDGSNKYYADSVKGRFTISRDNBKNLTLYLQMNSLRAEDTAVYYCAR----							
Consensus	(52)	WYDGSNKYYADSVKGRFTISRDNBKNLTLYLQMNSLRAEDTAVYYCAR							
								Section 3	
	(103)	103	110	126					
CR2-1.24.1_HC	(103)	SYGYVYDYGMDVWGQGTTVTVSS							
VH3-33	(99)	-----							
Consensus	(103)								

Figure 29B

								Section 1
	(1)	1	10	20	30	40	52	
CR2-1.24.1 LC	(1)	DIQMTQSPSSLSASVGDRVTITCRASQGIKNDLGWYQKPKGKAPKRLIYAAS						
A30	(1)	DIQMTQSPSSLSASVGDRVTITCRASQGIKNDLGWYQKPKGKAPKRLIYAAS						
Consensus	(1)	DIQMTQSPSSLSASVGDRVTITCRASQGIKNDLGWYQKPKGKAPKRLIYAAS						
								Section 2
	(53)	53	60	70	80	90	104	
CR2-1.24.1 LC	(53)	SLQSGVPSRFSGSGSGTEFTLTISSLQPEDPATYICLQHNNSYPWTFGQGTKV						
A30	(53)	SLQSGVPSRFSGSGSGTEFTLTISSLQPEDPATYICLQHNNSYP-----						
Consensus	(53)	SLQSGVPSRFSGSGSGTEFTLTISSLQPEDPATYICLQHNNSYP						
								Section 3
	(105)	1067						
CR2-1.24.1 LC	(105)	EIK						
A30	(96)	---						
Consensus	(105)							



10041360 .081302

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 30**Figure 30A**

Section 1						
	(1)	10	20	30	40	51
VH5-51	(1)	EVQLVQSGAEVKKRPGESLKI	SCKSGSYFTSYWIGWVRQMPGK	GLEWMGII		
CR2-1.25.1_HC	(1)	EVQLVQSGAEVKKRPGESLKI	SCKSGSYRFTSYWIGWVRQMPGK	GLEWMGII		
Consensus	(1)	EVQLVQSGAEVKKRPGESLKI	SCKSGSY	FTSYWIGWVRQMPGK	GLEWMGII	
Section 2						
	(52)	60	70	80	90	102
VH5-51	(52)	YPGDS DTRYSPSPFQSGQVTI	SADKSI	STAYLQWSSLKASDTAMYYCAR	----	
CR2-1.25.1_HC	(52)	YPGDS DTRYSPSPFQSGQVTI	SADKSI	STAYLQWSSLKASDTAMYYCAR	HGSY	
Consensus	(52)	YPGDS DTRYSPSPFQSGQVTI	SADKSI	STAYLQWSSLKASDTAMYYCAR		
Section 3						
	(103)	103	110	126		
VH5-51	(99)	-----				
CR2-1.25.1_HC	(103)	YYGSETYYNVFDYWGQGLVTVSS				
Consensus (103)						

Figure 30B

Section 1							
	(1)	10	20	30	40	52	
A30	(1)	DIQMTQSPSSLSASVGDRVTITCRASQGI	RNDLGWYQ	QKPGKAPKRLIYAAS			
CR2-1.25.1_LC	(1)	DIQMTQSPSSLSASVGDRVTITCRASQGI	RNDLGWYQ	QKPGKAPKRLIYAAS			
Consensus	(1)	DIQMTQSPSSLSASVGDRVTITCRASQGI	RNDLGWYQ	QKPGKAPKRLIYAAS			
Section 2							
	(53)	53	60	70	80	90	104
A30	(53)	SLQSGVPSRFSGSGSGTEFTLT	TISSIQPEDFATYYCLQHN	SYF-----			
CR2-1.25.1_LC	(53)	SLQSGVPSRFSGSGSGTEFTLT	TISSIQPEDFATYYCLQHN	SYF	PWTF	GGG	TKV
Consensus	(53)	SLQSGVPSRFSGSGSGTEFTLT	TISSIQPEDFATYYCLQHN	SYF			
Section 3							
	(105)	1067					
A30	(96)	---					
CR2-1.25.1_LC	(105)	EIK					
Consensus	(105)						



10041860.081302

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 31**Figure 31A**

							Section 1
	(1)	1	10	20	30	40	52
VH5-51	(1)	EVQLVQSGAEVKKPGEISLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIY					
CR2-1.29_HC	(1)	EVQLVQSGAEVKKPGEISLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIY					
Consensus	(1)	EVQLVQSGAEVKKPGEISLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIY					
							Section 2
	(53)	53	60	70	80	90	104
VH5-51	(53)	PGDS DTRYSPSPFQGGQTISADKSISTAYLQWSSILKASDTAMYICAR-----					
CR2-1.29_HC	(53)	PGDS DTRYSPSPFQGGQTISADKSISTAYLQWSSILKASDTAMYICARHVDVGA					
Consensus	(53)	PGDS DTRYSPSPFQGGQTISADKSISTAYLQWSSILKASDTAMYICAR					
							Section 3
	(105)	105	110	129			
VH5-51	(99)	-----					
CR2-1.29_HC	(105)	TIGGYYYYYHGM DVWGQGT TVTVSS					
Consensus	(105)						

Figure 31B

							Section 1
	(1)	1	10	20	30	40	53
A19	(1)	DIVMTQSPFLSLPVTPEGPASISCRSSQSLHNGYNYLDWYLQKPGQSPQLLI					
CR2-1.29_LC	(1)	DIVMTQSPFLSLPVTPEGPASISCRSSQSLHNGYNYLDWYLQKPGQSPQLLI					
Consensus	(1)	DIVMTQSPFLSLPVTPEGPASISCRSSQSLHNGYNYLDWYLQKPGQSPQLLI					
							Section 2
	(54)	54	60	70	80	90	106
A19	(54)	YLGSNRA SGVPDRFSGSGSGTDFTLKISRVEA DVG VYYCMQALQ P-----					
CR2-1.29_LC	(54)	YLGSNRA SGVPDRFSGSGSGTDFTLKISRVEA DVG VYYCMQALQ LMC SFGQ					
Consensus	(54)	YLGSNRA SGVPDRFSGSGSGTDFTLKISRVEAD DVG VYYCMQALQS					
							Section 3
	(107)	107	113				
A19	(101)	-----					
CR2-1.29_LC	(107)	GTKLEIK					
Consensus	(107)						



ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

10041860.081302

FIGURE 32

Figure 32A

Section 1					
	(1)	10	20	30	40
VH1-18	(1)	QUQLVQSGAEVRRPGASVKVSCRASGYTFTSYGTSWVRQAPGQGLEWMGWIS			52
CR2-1.33_HC	(1)	QUQLVQSGAEVKKPGASVKVSCRASGYTFTSYGISWVRQAPGQGLEWMGWIS			
Consensus	(1)	QUQLVQSGAEVKKPGASVKVSCRASGYTFTSYGISWVRQAPGQGLEWMGWIS			
Section 2					
	(53)	60	70	80	90
VH1-18	(53)	AYNGNTNYAQLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR-----			104
CR2-1.33_HC	(53)	AYNGNTNYAQLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDHYIDS			
Consensus	(53)	AYNGNTNYAQLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR			
Section 3					
	(105)	105	110	127	
VH1-18	(99)	-----			
CR2-1.33_HC	(105)	SDYLYYYXGLDVGQGTTVTVSS			
Consensus	(105)				

Figure 32B

Section 1					
	(1)	10	20	30	40
A20	(1)	DIQMTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQRPGKVPKLLIYAAS			53
CR2-1.33_LC	(1)	DIQMTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQRPGKVPKLLIYAAS			
Consensus	(1)	DIQMTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQRPGKVPKLLIYAAS			
Section 2					
	(54)	54	60	70	80
A20	(54)	LQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQKYNAP-----			106
CR2-1.33_LC	(54)	LQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQKYNAPELTFGGGTKEI			
Consensus	(54)	LQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQKYNAP			
Section 3					
	(107)	107			
A20	(96)	-			
CR2-1.33_LC	(107)	K			
Consensus	(107)				



10041860 081302
ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 33

Figure 33A

		Section 1					
	(1)	1	10	20	30	40	51
VH3-33	(1)	QVQLVESGGGVVQPGASLRRLSCAASGFTFSYGMHWVRQAPGKGLEWVAII					
CR2-1.38.1_HC	(1)	QVQLVESGGGVVQPGASLRRLSCAASGFTFSYGMHWVRQAPGKGLEWVAII					
Consensus	(1)	QVQLVESGGGVVQPGASLRRLSCAASGFTFSYGMHWVRQAPGKGLEWVAII					
		Section 2					
	(52)	52	60	70	80	90	102
VH3-33	(52)	WYDGSNRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR----					
CR2-1.38.1_HC	(52)	WYDGSNRYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGYYY					
Consensus	(52)	WYDG RYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAR					
		Section 3					
	(103)	103	110	127			
VH3-33	(99)	-----					
CR2-1.38.1_HC	(103)	DSSDYLYYYYGMDVWGQGTITVTVSS					
Consensus	(103)						

Figure 33B

								Section 1	
	(1)	1	10	20	30	40	52		
A20	(1)	DIQMTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQRKPGKVPKLLIYAAS							
CR2-1.38.1_LC	(1)	DIQMTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQRKPGKVENLLIYAAS							
Consensus	(1)	DIQMTQSPSSLSASVGDRVTITCRASQGISNYLAWYQQRKPGKVP LLIYAAS							
								Section 2	
	(53)	53	60	70	80	90	104		
A20	(53)	TLQSGVPSRFSGSGSGTDFTLTISSLQPEDVATYYCQRYNSAP-----							
CR2-1.38.1_LC	(53)	TLQSGVPSRFSGSGSGTDFTLTISSLQPEDVAAYCQKCNAPFTFGQGTIV							
Consensus	(53)	TLQSGVPSRFSGSGSGTDFTLTISSLQPEDVA YYCQK NSAP							
								Section 3	
	(105)	1057							
A20	(96)	---							
CR2-1.38.1_LC	(105)	EIK							
Consensus	(105)								



10041860 081302

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 34**Figure 34A**

								Section 1	
	(1)	1	10	20	30	40	51		
VH5-51	(1)	EVQLVQSGAEVKKPGEESLKIISCKGSGYSFTSYWIGWVRMPGKGLEWMGII							
CR2-1.39.1_HC	(1)	EVQLVQSGTEVKKPGEESLKIISCKGSGYRFTSYWIGWVRMPGKGLEWMGII							
Consensus	(1)	EVQLVQSG EVKKPGEESLKIISCKGSGY FTSYWIGWVRMPGKGLEWMGII							
								Section 2	
	(52)	52	60	70	80	90	102		
VH5-51	(52)	YPGDSSTRYSPPSQGVTTISADKSISTAYLQWSSLKASDTAMYYCAR----							
CR2-1.39.1_HC	(52)	YPGDSSTRYSPPSQGVTTISADKSISTAYLQWSSLKASDTAMYYCARHGSY							
Consensus	(52)	YPGDSSTRYSPPSQGVTTISADKSISTAYLQWSSLKASDTAMYYCAR							
								Section 3	
	(103)	103	110	126					
VH5-51	(99)	-----							
CR2-1.39.1_HC	(103)	YYNSGSYYNVFDYWGQGLTVTVSS							
Consensus	(103)								

Figure 34B

								Section 1	
	(1)	1	10	20	30	40	52		
A30	(1)	DIQMTQSPSSLSASVGDRTTTCRASQGIRNDLGWYQQKPGKAPKRLIYAAS							
CR2-1.39.1_LC	(1)	DIQMTQSPSSLSASVGDRTTTCRASQGIRNDLGWYQQKPGKAPKRLIYAAS							
Consensus	(1)	DIQMTQSPSSLSASVGDRTTTCRASQGIRNDLGWYQQKPGKAPKRLIYAAS							
								Section 2	
	(53)	53	60	70	80	90	104		
A30	(53)	SLQSGVPSRFSGSGSGTEFTLTISISLOPEDPATYYCLOHNSYP-----							
CR2-1.39.1_LC	(53)	SLQSGVPSRFSGSGSGTEFTLTISISLOPEDPATYYCLOHNSYPWTFGQGTKV							
Consensus	(53)	SLQSGVPSRFSGSGSGTEFTLTISISLOPEDPATYYCLOHNSYP							
								Section 3	
	(105)	1057							
A30	(96)	---							
CR2-1.39.1_LC	(105)	EIK							
Consensus	(105)								



ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF
Corvalan et al.
Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 35

Figure 35A

								Section 1
	(1)	1	10	20	30	40	52	
VH1-8	(1)	QVQLVQSGAEVKKRPGASVKVSKKASGYTFTSYDINWVRQATGQGLEWMGWMN						
CR2-1.45_HC	(1)	QVQLVQSGAEVKKRPGASVKVSKKASGYTFTSYDINWVRQATGQGLEWMGWMN						
Consensus	(1)	QVQLVQSGAEVKKRPGASVKVSKKASGYTFTSYDINWVRQATGQGLEWMGWMN						
								Section 2
	(53)	53	60	70	80	90	104	
VH1-8	(53)	PNSGNTGYAOKPQGRVTMTNTSISTAYMELSSLRSEDVAVYYCAR-----						
CR2-1.45_HC	(53)	PNSGNTGYAOKPQGRVTMTNTSISTAYMELSSLRSEDVAVYYCARGSGYSY						
Consensus	(53)	PNSGNTGYAOKPQGRVTMTNTSISTAYMELSSLRSEDVAVYYCAR						
								Section 3
	(105)	105	110	125				
VH1-8	(99)	-----						
CR2-1.45_HC	(105)	GYDYYYGMDVWGQGTTVTVSS						
Consensus	(105)							

Figure 35B

							Section 1
	(1)	1	10	20	30	40	53
A20	(1)	DIQMTQSPFSSLSASVGDRVITTCRASQGISNYLAWYQKPKGVPKLLIYAAS					
CR2-1.45_LC	(1)	DIQMTQSPFSSLSASVGDRVITINCRASQGISNDLAWYQKPKGVPKLLIYAAS					
Consensus	(1)	DIQMTQSPFSSLSASVGDRVITTCRASQGISN LAWYQKPKGVPKLLIYAAS					
							Section 2
	(54)	54	60	70	80	90	106
A20	(54)	LQSGVPSRFSGSGSGTDFTLTISISLQPEDVATYYCQKYNBAP-----					
CR2-1.45_LC	(54)	LQLGVPSRFSGSGSGTDFTLTISISLQPEDVATYYCQKYNBAPFTFGPGTKVDI					
Consensus	(54)	LQGVPSRFSGSGSGTDFTLTISISLQPEDVATYYCQKYNBAP					
							Section 3
	(107)	107					
A20	(96)	-					
CR2-1.45_LC	(107)	K					
Consensus	(107)						



10041860 . 081302

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 36**Figure 36A**

								Section 1	
	(1)	1	10	20	30	40	51		
VH1-8	(1)	QVQLVQSGAEVKKPGASVKVSCKASGYFTSYDINWVRQATGQGLEWMGWM							
CR2-1.46.1_HC	(1)	QVQLVQSGAEVKKPGASVKVSCKASGYFTSYDINWVRQATGQGLEWMGWM							
Consensus	(1)	QVQLVQSGAEVKKPGASVKVSCKASGYFTSYDINWVRQATGQGLEWMGWM							
								Section 2	
	(52)	52	60	70	80	90	102		
VH1-8	(52)	NPNSGNTGYAQKFGGRVTMTNRTSISTAYMELSSLRSEDVAVYYCAR----							
CR2-1.46.1_HC	(52)	NPNSGNTGYAQKFGGRVTMTNRTSISTAYMELSSLRSEDVAVYYCARDIVV							
Consensus	(52)	NPN GNTGYAQKFGGRVTMTNRTSISTAYMELSSLRSEDVAVYYCAR							
								Section 3	
	(103)	103	110	126					
VH1-8	(99)	-----							
CR2-1.46.1_HC	(103)	VVTATDYYYGMDVWGQTTVTVSS							
Consensus	(103)								

Figure 36B

								Section 1	
	(1)	1	10	20	30	40	52		
A30	(1)	DIQMTQSPSSSLASVGDRTITCRASQGIRNDLGWYQKPKAPKRLTFAAS							
CR2-1.46.1_LC	(1)	DIQMTQSPSSSLASVGDRTITCRASQGIRNDLGWYQKPKAPKRLTFAAS							
Consensus	(1)	DIQMTQSPSSSLASVGDRTITCRASQGIRNDLGWYQKPKAPKRLTFAAS							
								Section 2	
	(53)	53	60	70	80	90	104		
A30	(53)	SLQSGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHNSTP-----							
CR2-1.46.1_LC	(53)	SLPESGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQHSYPTTFGQGTKV							
Consensus	(53)	SL SGVPSRFSGSGSGTEFTLTISSLQPEDFATYYCLQH YP							
								Section 3	
	(105)	1087							
A30	(96)	---							
CR2-1.46.1_LC	(105)	EIK							
Consensus	(105)								



1004-1960, 081302

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 37**Figure 37A**

							Section 1
	(1)	1	10	20	30	40	51
CR2-1.48.1_HC	(1)	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGGQGLEWMGWI					
VH1-18	(1)	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGGQGLEWMGWI					
Consensus	(1)	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGGQGLEWMGWI					
							Section 2
	(52)	52	60	70	80	90	102
CR2-1.48.1_HC	(52)	SAYNGNTNYAQKLGGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDVEY					
VH1-18	(52)	SAYNGNTNYAQKLGGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR---					
Consensus	(52)	SAYNGNTNYAQKLGGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCAR					
							Section 3
	(103)	103	110	125			
CR2-1.48.1_HC	(103)	YYDGSGLYYFDYWGQGLTVVSS					
VH1-18	(99)	-----					
Consensus	(103)						

Figure 37B

		Section 1				
	(1)	1	10	20	30	40 52
CR2-1.48.1_LC	(1)	DIQMTQSPSSVSASVGDRTITCRASQGISWLAHWYQKPKAPKLLIYAAS				
L5	(1)	DIQMTQSPSSVSASVGDRTITCRASQGISWLAHWYQKPKAPKLLIYAAS				
Consensus	(1)	DIQMTQSPSSVSASVGDRTITCRASQGISWLAHWYQKPKAPKLLIYAAS				
		Section 2				
	(53)	53	60	70	80	90 104
CR2-1.48.1_LC	(53)	ILQSGVPSRFSGSGSGTDFTLTISLQPEDFAFYCQQNSFPRTFGQGTKV				
L5	(53)	SLQSGVPSRFSGSGSGTDFTLTISLQPEDFAFYCQQNSFP-----				
Consensus	(53)	LQSGVPSRFSGSGSGTDFTLTISLQPEDFASYCQQANSFP				
		Section 3				
	(105)	1067				
CR2-1.48.1_LC	(105)	EIK				
L5	(96)	---				
Consensus	(105)					



10041860 081302
ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 38

Figure 38A

Section 1						
	(1)	1	10	20	30	40 51
CR2-1.49.1_HC	(1)	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWM				
VH1-8	(1)	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWM				
Consensus	(1)	QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDINWVRQATGQGLEWMGWM				
Section 2						
	(52)	52	60	70	80	90 102
CR2-1.49.1_HC	(52)	NPNSGDTGYAQKFGGRVTMTNTSISTAYMELSSLRSEITAVYFCARMRDI				
VH1-8	(52)	NPNSGNTGYAQKFGGRVTMTNTSISTAYMELSSLRSEITAVYFCAR----				
Consensus	(52)	NPNSG TGYAQKFGGRVTMTNTSISTAYMELSSLRSEITAVYFCAR				
Section 3						
	(103)	103	110	127		
CR2-1.49.1_HC	(103)	VATSYYYYFYGMVDVWGQGTITVTVSS				
VH1-8	(99)	-----				
Consensus	(103)					

Figure 38B

										Section 1	
		(1)	1	10	20	30	40	52			
CR2-1.49.1_LC	(1)	DIVMTQBELSLVTEGEFASISCRSSQSLLHSGNYNYLDWYLLKPGQSPQLL									
A19	(1)	DIVMTQBELSLVTPGEPASISCRSSQSLLHSGNYNYLDWYLLKPGQSPQLL									
Consensus	(1)	DIVMTQBELSLPVTPGEPASISCRSSQSLLHSGNYNYLDWYLLKPGQSPQLL									
										Section 2	
		(53)	53	60	70	80	90	104			
CR2-1.49.1_LC	(53)	IYLGSSRASGVDPDRPSGSGSGTDFTLKISRVEAEDVGVIYCMQITITITFGQ									
A19	(53)	IYLGSSRASGVDPDRPSGSGSGTDFTLKISRVEAEDVGVIYCMQALQTP----									
Consensus	(53)	IYLGSSRASGVDPDRPSGSGSGTDFTLKISRVEAEDVGVIYCMQLQT									
										Section 3	
		(105)	105	111							
CR2-1.49.1_LC	(105)	GTRLEIK									
A19	(101)	-----									
Consensus	(105)										



10041860 .031302

ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan et al.


Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 39**Figure 39A**

								Section 1	
	(1)	1	10	20	30	40	51		
CR2-1.51.1 HC	(1)	EVQLVQSGAEVKKRPGESLKISCKGSGYSFTSYWIGWVRMPGKGLEWMGII							
VH5-51	(1)	EVQLVQSGAEVKKRPGESLKISCKGSGYSFTSYWIGWVRMPGKGLEWMGII							
Consensus	(1)	EVQLVQSGAEVKKRPGESLKISCKGSGYSFTSYWIGWVRMPGKGLEWMGII							
								Section 2	
	(52)	52	60	70	80	90	102		
CR2-1.51.1 HC	(52)	YFGDSDA YSPSFQSQVTISADKSIISTAYLQWSSLKASDTAMYYCARHYDY							
VH5-51	(52)	YFGDSDT YSPSFQSQVTISADKSIISTAYLQWSSLKASDTAMYYCAR----							
Consensus	(52)	YFGDSD K YSPSFQSQVTISADKSIISTAYLQWSSLKASDTAMYYCAR							
								Section 3	
	(103)	103	110	126					
CR2-1.51.1_HC	(103)	VWRNYRYTGWFDPWGQGLTVTVSS							
VH5-51	(99)	-----							
Consensus (103)									

Figure 39B

								Section 1
	(1)	1	10	20	30	40	52	
CR2-1.51.1 LC	(1)	EIVLTQSPGTLISLSPGERATLSCRAGQSIVSSSYLAWYQOKPGQAPRLIIYGA						
A27	(1)	EIVLTQSPGTLISLSPGERATLSCRAGQSIVSSSYLAWYQOKPGQAPRLIIYGA						
Consensus	(1)	EIVLTQSPGTLISLSPGERATLSCRAGQSIVSSSYLAWYQOKPGQAPRLIIYGA						
								Section 2
	(53)	53	60	70	80	90	104	
CR2-1.51.1 LC	(53)	SNRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSLPFGPGTK						
A27	(53)	SNRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSP-----						
Consensus	(53)	S RATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSS						
								Section 3
	(105)	10508						
CR2-1.51.1 LC	(105)	VDIK						
A27	(97)	----						
Consensus	(105)							



Corvalan et al.

Appl. No.: 10/041,860 Atty Docket: ABGENLX.051A

FIGURE 40

Figure 40A

	(1)	10	20	30	40	52	Section 1
Cur2-6.4.1_hc	(1) QVQLVQSGAEVVRKFGASVKVSCASGYTFTSYDINWVRQATGGGLEWMGWIN						
VH1-8	(1) QVQLVQSGAEVVRKFGASVKVSCASGYTFTSYDINWVRQATGGGLEWMGWIN						
Consensus	(1) QVQLVQSGAEVVRKFGASVKVSCASGYTFTSYDINWVRQATGGGLEWMGWIN						

	(53)	60	70	80	90	104	Section 2
Cur2-6.4.1_hc	(53) PNSGNTDYAQKFGQGRVTMTRTTSISTAYMELSSLRSEDTAIYYCVRGFGYSY						
VH1-8	(53) PNSGNTGYAQKFGQGRVTMTRTTSISTAYMELSSLRSEDTAIYYCAR-----						
Consensus	(53) PNSGNT YAQKFGQGRVTMTR TSISTAYMELSSLRSEDTAIYYC R						

	(105)	105	110	125	Section 3
Cur2-6.4.1_hc	(105) NYDYYYGMDVVGQGTTVTVSS				
VH1-8	(99) -----				
Consensus	(105)				

Figure 40B

		Section 1						
		(1)	10	20	30	40	52	
Cur2-6.4.1 Lc	(1)	EIVLTQSPGTL SL SPGERATL SC RASQSV SS SYLAWYQQRFGQAPRLITY T						
A27	(1)	EIVLTQSPGTL SL SPGERATL SC RASQSV SS SYLAWYQQRFGQAPRLITY CA						
Consensus	(1)	EIVLTQSPGTL SL SPGERATL SC RASQSV SS SYLAWYQQRFGQAPRLITY A						
		Section 2						
		(53)	53	60	70	80	90	104
Cur2-6.4.1 Lc	(53)	SSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY Y CQQYGS SP CFSGG TK						
A27	(53)	SSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY Y CQQYGS SP -----						
Consensus	(53)	SSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVY Y CQQYGS SP						
		Section 3						
		(105)	10308					
Cur2-6.4.1 Lc	(105)	LEIK						
A27	(97)	----						
Consensus	(105)							

Figure 41A

CLONE #	VH	#DE L	VH END	# N's	N Sequence	DH	Size of D	D Sequence	# N's	N Sequence	JH	# del	JH Segment
1.19.1	DP-15/1-8	-1	CGAGAG (SEQ ID NO:92)	3	ACG	D3-16	28	TTATGATTACGTTT GGGGAGTTATCGT (SEQ ID NO:93)	2	GC	JH6 B	-12	ACTACG (SEQ ID NO:94)
1.19.2	DP-15/1-8	-1	CGAGAG (SEQ ID NO:92)	3	ACG	D3-16	28	TTATGATTACGTTT GGGGAGTTATCGT (SEQ ID NO:93)	2	GC	JH6 B	-12	ACTACG (SEQ ID NO:94)
1.19.3	DP-15/1-8	-1	CGAGAG (SEQ ID NO:92)	3	ACG	D3-16	28	TTATGATTACGTTT GGGGAGTTATCGT (SEQ ID NO:93)	2	GC	JH6 B	-12	ACTACG (SEQ ID NO:94)
6.4.1	DP-15/1-8	0	GAGAGG (SEQ ID NO:95)	3	CTT	D5-18	12	TGATACAGCTA (SEQ ID NO:96)	2	TA	JH6 B	0	ATTACTAC (SEQ ID NO:97)
6.4.2	DP-15/1-8	0	GAGAGG (SEQ ID NO:95)	3	CTT	D5-18	12	TGATACAGCTA (SEQ ID NO:96)	2	TA	JH6 B	0	ATTACTAC (SEQ ID NO:97)
6.4.3	DP-15/1-8	0	GAGAGG (SEQ ID NO:95)	3	CTT	D5-18	12	TGATACAGCTA (SEQ ID NO:96)	2	TA	JH6 B	0	ATTACTAC (SEQ ID NO:97)

CLONE	Vk	#de	Vk end	#n	N SEQ	Jk	# del	JK end
-------	----	-----	--------	----	-------	----	-------	--------

1.19.1	A30	-3	TTACCC (SEQ ID NO:98)	6	GTGCAG (SEQ ID NO:99)	JK2	-7	TTTTGG (SEQ ID NO:100)
1.19.2	A30	-3	TTACCC (SEQ ID NO:98)	6	GTGCAG (SEQ ID NO:99)	JK2	-7	TTTTGG (SEQ ID NO:100)



20041860 05041860



Figure 41B

1.19. 3	A30	-3	TTACCC (SEQ ID NO:98)	6	GTGCAG (SEQ ID NO:99)	JK2	-7	TTTTGG (SEQ ID NO:100)
6.4.1	A27/A27A	-3	CTCACC (SEQ ID NO:101)	6	GTGCAG (SEQ ID NO:102)	JK2	-7	TTTTGG (SEQ ID NO:103)
6.4.2	A27/A27A	-3	CTCACC (SEQ ID NO:101)	6	GTGCAG (SEQ ID NO:102)	JK2	-7	TTTTGG (SEQ ID NO:103)
6.4.3	A27/A27A	-3	CTCACC (SEQ ID NO:101)	6	GTGCAG (SEQ ID NO:102)	JK2	-7	TTTTGG (SEQ ID NO:103)

20041860 000002

Figure 42A

CLONE #	VH	#DEL	VH END	# N's	N Sequence	DH	Size of D	D Sequence	# N's	N Sequence	JH	# del	JH Segment
1.6.1	DP-77/3-21	0	GAGAGA (SEQ ID NO:104)	0	0	D3-16	22	TATTATGATTAC GTTTGGGGGA (SEQ ID NO:105)	14	ATTATCGCC TCGTT (SEQ ID NO:106)	JH4B	-1	CTACTT (SEQ ID NO:107)
1.6.1	DP-77/3-21	0	GAGAGA (SEQ ID NO:104)	0	0	D3-16	22	TATTATGATTAC GTTTGGGGGA (SEQ ID NO:105)	14	ATTATCGCC TCGTT (SEQ ID NO:106)	JH4B	-1	CTACTT (SEQ ID NO:107)
1.6.1	DP-77/3-21	0	GAGAGA (SEQ ID NO:104)	0	0	D3-16	22	TATTATGATTAC GTTTGGGGGA (SEQ ID NO:105)	14	ATTATCGCC TCGTT (SEQ ID NO:106)	JH4B	-1	CTACTT (SEQ ID NO:107)
1.11.1	DP-42/3-53	-5	AGAGA (SEQ ID NO:108)	3	GGA	D4-17	10	ACGGTGACTA (SEQ ID NO:109)	5	GGAAT (SEQ ID NO:110)	JH6B	-2	TACTACT A (SEQ ID NO:111)
1.11.2	DP-42/3-53	-5	AGAGA (SEQ ID NO:108)	3	GGA	D4-17	10	ACGGTGACTA (SEQ ID NO:109)	5	GGAAT (SEQ ID NO:110)	JH6B	-2	TACTACT A (SEQ ID NO:111)
1.23.1	DP-73/5-51	0	GAGACA (SEQ ID NO:112)	18	TGTATCGTATTACT ATGT (SEQ ID NO:113)	D3-10	19	TTCGGGGAGTTA TTATAAC (SEQ ID NO:114)	2	GT	JH4B	-4	CTTTGA (SEQ ID NO:115)
1.23.2	DP-73/5-51	0	GAGACA (SEQ ID NO:112)	18	TGTATCGTATTACT ATGT (SEQ ID NO:113)	D3-10	19	TTCGGGGAGTTA TTATAAC (SEQ ID NO:114)	2	GT	JH4B	-4	CTTTGA (SEQ ID NO:115)





				#n				
1.6.1	A30	-3	TTACCC (SEQ ID NO:116)	0	0	JK4	0	GCTCACT (SEQ ID NO:117)
1.6.2	A30	-3	TTACCC (SEQ ID NO:116)	0	0	JK4	0	GCTCACT (SEQ ID NO:117)
1.6.3	A30	-3	TTACCC (SEQ ID NO:116)	0	0	JK4	0	GCTCACT (SEQ ID NO:117)
1.11.1	A3/A19/DPK	-4	AAACTC (SEQ ID NO:118)	0	0	JK4	-2	TCACTTTC (SEQ ID NO:119)
1.11.2	A3/A19/DPK	-4	AAACTC (SEQ ID NO:118)	0	0	JK4	-2	TCACTTTC (SEQ ID NO:119)
1.23.1	A30	-3	TTACCC (SEQ ID NO:120)	0	0	JK1	0	GTGGAC (SEQ ID NO:120)
1.23.2	A30	-3	TTACCC (SEQ ID NO:120)	0	0	JK1	0	GTGGAC (SEQ ID NO:120)

Figure 42B

203180, 09314001



Figure 43A

CLONE #	VH	#DEL	VH END	#N's	N Sequence	DH	Size of D	D Sequence	#N's	N Sequence	JH	#del	JH Segment
1.17.1	DP-50/3-33	0	GAGAGA (SEQ ID NO:121)	4	TCAA	D5-18	8	GGATACA (SEQ ID NO:122)	9	ATATGCTG G (SEQ ID NO:123)	JH6B	-1	TTACTACT (SEQ ID NO:124)
1.17.2	DP-50/3-33	0	GAGAGA (SEQ ID NO:121)	4	TCAA	D5-18	8	GGATACA (SEQ ID NO:122)	9	ATATGCTG G (SEQ ID NO:123)	JH6B	-1	TTACTACT (SEQ ID NO:124)
1.17.3	DP-50/3-33	0	GAGAGA (SEQ ID NO:121)	4	TCAA	D5-18	8	GGATACA (SEQ ID NO:122)	9	ATATGCTG G (SEQ ID NO:123)	JH6B	-1	TTACTACT (SEQ ID NO:124)
1.18	DP-15/1-8	1	CGAGAG (SEQ ID NO:125)	1	A	D8-19	19	GGGTATAG CAGTGGCT GG (SEQ ID NO:126)	4	GACA	JH6B	-2	TACTAC (SEQ ID NO:127)
1.24.1	DP-50/3-33	0	GAGAGA (SEQ ID NO:128)	4	TCAG	DK4	18	GGATACAG CTATGGTT AC (SEQ ID NO:129)	2	GT	JH6B	-4	CTACTA (SEQ ID NO:130)
1.24.2	DP-50/3-33	0	GAGAGA (SEQ ID NO:128)	4	TCAG	DK4	18	GGATACAG CTATGGTT AC (SEQ ID NO:129)	2	GT	JH6B	-4	CTACTA (SEQ ID NO:130)
1.25.1	DP-73/5-51	0	GAGACA (SEQ ID NO:131)	6	TGGATC (SEQ ID NO:132)	D3-10	30	GTATATTA TGGTTCGG AGACTTATT ATAA	3	TGT	JH4B	-4	CTTTGA (SEQ ID NO:135)

10041860, 081302



Figure 43B

CLONE #	VH	#DEL	VH END	#N's	N Sequence	DH	Size of D	D Sequence	#N's	N Sequence	JH	#del	JH Segment
1.25.2	DP-73/5-51	0	GAGACA (SEQ ID NO:131)	6	TGGATC (SEQ ID NO:132)	D3-10	30	(SEQ ID NO:133) GTATATTA TGGTTCGG AGACTTATT ATAA (SEQ ID NO:133)	3	TGT	JH4B	-4	CTTTGA (SEQ ID NO:134)
1.28	DP-73/5-51	0	GAGACA (SEQ ID NO:135)	1	C	D5-12	21	GTGGATgT AGGGGCT ACGATT (SEQ ID NO:136)	7	GGGGAT (SEQ ID NO:137)	JH6B	0	ATTACTAC (SEQ ID NO:138)
1.33	DP-14/1-18	0	GAGAGA (SEQ ID NO:139)	2	TC	D21-9	18	ATTACTAT GATAGTAG TG (SEQ ID NO:140)	7	ATTATCT (SEQ ID NO:141)	JH6B	-4	CTACTA (SEQ ID NO:142)
1.38.1	DP-50/3-33	1	CGAGAG (SEQ ID NO:143)	2	GA	D21-9	19	TATTACTA TGATAGTA GTG (SEQ ID NO:144)	7	ATTATCT (SEQ ID NO:145)	JH6B	-4	CTACTA (SEQ ID NO:146)
1.38.1	DP-73/5-51	0	GAGACA (SEQ ID NO:147)	6	TGGATC (SEQ ID NO:148)	D3-10	31	GTATTACT ATaaTTCG GGGAGTTA TTATAAC (SEQ ID NO:149)	2	GT	JH4B	-4	CTTTGA (SEQ ID NO:150)
1.38.2	DP-73/5-51	0	GAGACA (SEQ ID NO:147)	6	TGGATC (SEQ ID NO:148)	D3-10	31	GTATTACT ATaaTTCG GGGAGTTA TTATAAC (SEQ ID NO:149)	2	GT	JH4B	-4	CTTTGA (SEQ ID NO:150)

10041860 - 001302



Figure 43C

CLONE #	VH	#DEL	VH END	#N's	N Sequence	DH	Size of D	D Sequence	#N's	N Sequence	JH	#del	JH Segment
1.40.1	DP-16/1-8	1	CGAGAG (SEQ ID NO:151)	0	0	D2	25	ATATTGTA GTGGTGGT AGCTGCTA C (SEQ ID NO:152)	2	CA	JH6B	-6	ACTACT (SEQ ID NO:153)
1.40.2	DP-16/1-8	1	CGAGAG (SEQ ID NO:151)	0	0	D2	25	ATATTGTA GTGGTGGT AGCTGCTA C (SEQ ID NO:152)	2	CA	JH6B	-6	ACTACT (SEQ ID NO:153)
1.45	DP-16/1-8	0	GAGAGG (SEQ ID NO:154)	2	CA	DK4	20	GTGGATAC AGCTATGG TTAC (SEQ ID NO:155)	1	G	JH6B	-6	ACTACT (SEQ ID NO:156)
1.46.1	DP-16/1-8	1	CGAGAG (SEQ ID NO:157)	0	0	D2	25	ATATTGTA GT GGTGGTA GCTGCTAC (SEQ ID NO:158)	2	GG	JH6B	-6	ACTACT (SEQ ID NO:159)
1.46.2	DP-16/1-8	1	CGAGAG (SEQ ID NO:157)	0	0	D2	25	ATATTGTA GTGGTGGT AGCTGCTA C (SEQ ID NO:158)	2	GG	JH6B	-6	ACTACT (SEQ ID NO:159)
1.46.1	DP-14/1-18	1	CGAGAG (SEQ ID NO:160)	7	TGTTGAA (SEQ ID NO:161)	D21-9	20	TATTACTA TGATgGTA GTGGTTAT (SEQ ID NO:162)	1	T	JH4B	0	ACTACT (SEQ ID NO:163)
1.46.2	DP-14/1-18	1	CGAGAG	7	TGTTGAA	D21-9	20	TATTACTA	1	T	JH4B	0	ACTACT

10041860 - 001302

Figure 43D

CLONE #	VH	#DEL	VH END (SEQ ID NO:160)	#N's	N Sequence (SEQ ID NO:161)	DH	Size of D	D Sequence (SEQ ID NO:162)	#N's	N Sequence	JH	#del	JH Segment (SEQ ID NO:163)
1.49.1	DP-15/1-8	2	GCGAGA (SEQ ID NO:164)	5	ATGAG (SEQ ID NO:165)	D5-12	17	GGATATAG A (SEQ ID NO:166)	3	GCT	JH6B	0	ATTACTAC (SEQ ID NO:167)
1.49.2	DP-15/1-8	2	GCGAGA (SEQ ID NO:164)	5	ATGAG (SEQ ID NO:165)	D5-12	17	GGATATAG A (SEQ ID NO:166)	3	GCT	JH6B	0	ATTACTAC (SEQ ID NO:167)
1.51.1	DP-73/5-51	0	GAGACA (SEQ ID NO:168)	1	C	D3-16	31	TATGATTA CGTTTGGa GGAATTAT CGGTATA (SEQ ID NO:169)	5	CAGGG (SEQ ID NO:170)	JH5B	-5	TGGTTC (SEQ ID NO:171)
1.51.2	DP-73/5-51	0	GAGACA (SEQ ID NO:168)	1	C	D3-16	31	TATGATTA CGTTTGGa GGAATTAT CGGTATA (SEQ ID NO:169)	5	CAGGG (SEQ ID NO:170)	JH5B	-5	TGGTTC (SEQ ID NO:171)

CLONE	vk	#del	vk end	#n	N SEQ	JK	#del	JK end
-------	----	------	--------	----	-------	----	------	--------

1.17.1	A30	3	TTACCC (SEQ ID NO:172)	0	0	JK4	0	GCTCACT (SEQ ID NO:173)
--------	-----	---	---------------------------	---	---	-----	---	----------------------------



10041860, 0001302



Figure 43E

CLONE	Vk	#del	Vk end	#n	N SEQ	JK	# del	JK end
1.17.2	A30	3	TTACCC (SEQ ID NO:172)	0	0	JK4	0	GCTCACT (SEQ ID NO:173)
1.17.3	A30	3	TTACCC (SEQ ID NO:172)	0	0	JK4	0	GCTCACT (SEQ ID NO:173)
1.18	A30	3	TTACCC (SEQ ID NO:174)	0	0	JK3	0	ATTGAC (SEQ ID NO:175)
1.24.1	A30	3	TTACCC (SEQ ID NO:176)	0	0	JK1	0	GTGGAC (SEQ ID NO:177)
1.24.2	A30	3	TTACCC (SEQ ID NO:176)	0	0	JK1	0	GTGGAC (SEQ ID NO:177)
1.25.1	A30	3	TTACCC (SEQ ID NO:178)	0	0	JK1	0	GTGGAC (SEQ ID NO:179)
1.25.2	A30	3	TTACCC (SEQ ID NO:178)	0	0	JK1	0	GTGGAC (SEQ ID NO:179)
1.29	A3/A19/DPK	7	CTACAA (SEQ ID NO:180)	14	TCTCTCATG TGCAG (SEQ ID NO:181)	JK2	-7	TTTTGG (SEQ ID NO:182)
1.33	A20/DPK4	3	TGCCCC (SEQ ID NO:183)	0	0	JK4	0	GCTCAC (SEQ ID NO:184)
1.38.1	A20/DPK4	3	TGCCCC (SEQ ID NO:185)	0	0	JK1	0	GTGGAC (SEQ ID NO:186)
1.39.1	A30	3	TTACCC (SEQ ID NO:187)	0	0	JK1	0	GTGGAC (SEQ ID NO:188)

10041860 081302




Figure 43F

CLONE	vk	#del	vk end (SEQ ID NO:187)	#n	N SEQ	JK	#del	JK end (SEQ ID NO:188)
1.39.2	A30	3	TTACCC (SEQ ID NO:187)	0	0	JK1	0	GTGGAC (SEQ ID NO:188)
1.45	A20/DPK4	3	TGCCCC (SEQ ID NO:189)	0	0	JK3	0	ATTCAC (SEQ ID NO:190)
1.46.1	A30	0	CCCTCC (SEQ ID NO:191)	0	0	JK1	-3	GACGTT (SEQ ID NO:192)
1.46.2	A30	0	CCCTCC (SEQ ID NO:191)	0	0	JK1	-3	GACGTT (SEQ ID NO:192)
1.48.1	L5/DPK5V	1	TCCCTC (SEQ ID NO:193)	0	0	JK1	-2	GGACGTT (SEQ ID NO:194)
1.48.2	L5/DPK5V	1	TCCCTC (SEQ ID NO:193)	0	0	JK1	-2	GGACGTT (SEQ ID NO:194)
1.49.1	A3/A19/DPK	5	CAAACT (SEQ ID NO:195)	0	0	JK5	-1	ATCACC (SEQ ID NO:196)
1.49.2	A3/A19/DPK	5	CAAACT (SEQ ID NO:195)	0	0	JK5	-1	ATCACC (SEQ ID NO:196)
1.51.1	A27/A27A	4	GCTCAC (SEQ ID NO:197)	1	T	JK3	0	ATTCAC (SEQ ID NO:198)
1.51.1	A27/A27A	4	GCTCAC (SEQ ID NO:197)	1	T	JK3	0	ATTCAC (SEQ ID NO:198)

10041860.081302



AUG 13 2002
 PATENT & TRADEMARK OFFICE

FIGURE 44



10041860 081302


FIGURE 45



200180 09874001




FIGURE 46



20180109 09:44:01



FIGURE 47



203180 09814001



ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan, et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

10041860 001302

FIGURE 48

1.19 H	1	Q	A	A V V K	T	D N	T Q	WMNPNSGN G	60
6.4 H	1	Q	A	A V V K	T	D N	T Q	WINPNSGN D	60
1.18 H	1	Q	A	A V V K	T	D N	T Q	WMNPNSGN G	60
1.40 H	1	Q	A	A V V K	T	T D N	T Q	WMNPNSGN G	60
1.45 H	1	Q	A	A V V K	T	D N	T Q	WMNPNSGN G	60
1.46 H	1	Q	A	A V V K	S	D N	T Q	WMNPNNGN G	60
1.49 H	1	Q	A	A V V K	T	D N	T Q	WMNPNSGD G	60
1.33 H	1	Q	A	A V V K	T	G S	P Q	WISAYNGN N	60
1.48 H	1	Q	A	A V V K	T	G S	P Q	WISAYNGN N	60
1.6 H	1	E	E GGLV	G LRL A	FN RT	NMN	P K	VSSISSSSSNIY	60
1.17 H	1	Q	E GG VQ	K LRL A	FT S	GMH	P K	VAVIWDGSKY	60
1.24 H	1	Q	E GG VQ	R LRL A	FS S	GMH	P K	VADIWDGSKY	60
1.38 H	1	Q	E GG VQ	R LRL A	FT S	GMH	P K	VAVIWDGNDKY	60
1.11 H	1	E	GGLIQ	G LRL A	FTVS	NYMS	P K	VSVIYSGGS- Y	59
1.23 H	1	E	A	E L I EG	S	W G	MP K	IIYPGDS R	60
1.25 H	1	E	A	E L I KG	R	W G	MP K	IIYPGDS R	60
1.29 H	1	E	A	E L I KG	S	W G	MP K	IIYPGDS R	60
1.39 H	1	E	T	E L I KG	R	W G	MP K	IIYPGDS R	60
1.51 H	1	E	A	E L I KG	S	W G	MP K	IIYPGDSDAK	60

[CDR1]

[CDR2]

1.19 H	61	QKF	V MTRNT I	MELS	SE	V	--DVM-ITFGGVIVH-YGM V	116
6.4 H	61	QKF	V MTRDT I	MELS	SE	I V	--GFG-YSYN-YD -YGM V	115
1.18 H	61	QKF	V MTRNT I	MELS	SE	V	--EG--IAVAGTY YYGM V	116
1.40 H	61	QKF	V MTRNT L	MELS	SE	V	--DIV-VVVAATN -NGM V	116
1.45 H	61	QKF	V MTRNT I	MELS	SE	V	--GSG-YSYG-YD -YGM V	115
1.46 H	61	QKF	V MTRNT I	MELS	SE	V	--DIV-VVVTATD -YGM V	116
1.49 H	61	QKF	V MTRNT I	MELS	SE	V F	--MRD-IVATSYY FYGM V	117
1.33 H	61	QKL	V MTTDT T	MELR	SD	V	--DHY-YDSSDYL YYGL V	117
1.48 H	61	QKL	V MTTDT T	MELR	SD	V	DVEYY-YDGSYY FDY----	115
1.6 H	61	DSVK	F ISRDNAKNSL	LQMN	AE	V	DIMI---TFG-GIIASFYF Y	116
1.17 H	61	DSVK	F ISRDN KN L	LQMN	AE	V	DQGY---RYA-GY DYGM V	116
1.24 H	61	DSVK	F ISRDN KN L	LQMN	AE	V	DQGY---SYG-YV DYGM V	116
1.38 H	61	DSVK	F VSRDN KN L	LQMN	AE	V	GYYYD--SSD-YL YYGM V	117
1.11 H	60	DSVK	F ISRDN KN L	LQMN	AE	V	GTVTT-----N YYGM V	110
1.23 H	61	SPSF	QV ISADK I	LQWS	KAS	M	HVSY---YYVSGS -NVF Y	116
1.25 H	61	SPSF	QV ISADK I	LQWS	KAS	M	HGSY---YYGSET -NVF Y	116
1.29 H	61	SPSF	QA ISADK I	LQWS	KAS	M	HVDVGATIGGYYY -HGM V	119
1.39 H	61	SPSF	QV ISADK I	LQWS	KAS	M	HGSY---YYNSGS -NVF Y	116
1.51 H	61	SPSF	QV ISADK I	LQWS	KAS	M	HYDY---VWRNYR T-GWF P	116

[CDR3]



ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan, et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 48 (CONT)

1.19 H	117	T	126
6.4 H	116	T	125
1.18 H	117	T	126
1.40 H	117	T	126
1.45 H	116	T	125
1.46 H	117	T	126
1.49 H	118	T	127
1.33 H	118	T	127
1.48 H	116	L	125
1.6 H	117	L	126
1.17 H	117	T	126
1.24 H	117	T	126
1.38 H	118	T	127
1.11 H	111	T	120
1.23 H	117	L	126
1.25 H	117	L	126
1.29 H	120	T	129
1.39 H	117	L	126
1.51 H	117	L	126



ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan, et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

10041860-0001302

FIGURE 49

1.48 L	1		V		T	SS-----W A	A KL	I Q 55
1.49 L	1	V	L	PVTP EPAS	S S	SLLHSNGYNY D LL	QS QL	LG SRA 60
1.11 L	1	V	L	PVTP EPAS	S S	SLLQSNGYNY D L	QS QL	LG NRA 60
1.29 L	1	V	L	PVTP EPAS	S S	SLLHSNGYNY D L	QS QL	LG NRA 60
1.45 L	1				N	SN-----D A	V KL	T Q 55
1.33 L	1				T	SN-----Y A	V KL	T Q 55
1.38 L	1				T	SN-----Y A	V NL	T Q 55
6.4 L	1	E VL	GT	L P E A	LS	SVSSS-----Y A	QA RL	T SRA 56
1.51 L	1	E VL	GT	L P E A	LS	SVSSS-----Y A	QA RL	G NRA 56
1.19 L	1				T	RN-----D G	A KR	S Q 55
1.18 L	1				T	RN-----D G	A KR	S Q 55
1.16 L	1				T	RN-----D G F	A KR	S Q 55
1.23 L	1				T	RN-----D G	I A KR	S Q 55
1.25 L	1				T	RN-----D G	A KR	S Q 55
1.39 L	1				T	RN-----D G	A KR	S Q 55
1.17 L	1				T	RN-----D G	A KR	S Q 55
1.24 L	1				T	RN-----D G	A KR	S Q 55
1.46 L	1				T	RN-----D G	A KR	F S P 55

[CDR1] [CDR2]

1.48 L	56		D		F S	Q SN F R -	Q	107
1.49 L	61	D	D	K RVEA	VG V	M TLQTIT--	Q RL	111
1.11 L	61	D	D	K RVEA	VG V	M ALQTLT--	G	111
1.29 L	61	D	D	K RVEAD	VG V	M ALQSLMCS	Q L	113
1.45 L	56	L	D		V T	QKYN A F -	P D	107
1.33 L	56		D		V T	QKYN A L -	G	107
1.38 L	56		D S		V A	QKCN A W -	Q T	107
6.4 L	57	T I D	D	R E	F V	Q YG S CS-	Q L	108
1.51 L	57	T I D	D	R E	F V	Q YG SLF -	P D	108
1.19 L	56		D		F T	L HN D CS-	Q L R	107
1.18 L	56		E		F T F	L HN Y F -	P D	107
1.16 L	56		E		F T	L HN Y L -	G	107
1.23 L	56	R	E		F T	L HN Y W -	Q	107
1.25 L	56		E		F T	L HN Y W -	Q	107
1.39 L	56		E		F T	L HN Y W -	Q	107
1.17 L	56		E		F T	L HN Y L -	G	107
1.24 L	56		E		F T	L HN Y W -	Q	107
1.46 L	56		E		F T	L HSGY P -	Q	107

[CDR3]



10024-1360-000130
ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF
Corvalan, et al.
Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 51

1.33 H	1								60
1.48 H	1								60
				[CDR1]				[CDR2]	
1.33 H	61							--DH S D L YY GLDV	118
1.48 H	61							DVEY G G Y FD ----	116
								[CDR3]	
1.33 H	119	T							
1.48 H	117	L							



10041860 0031302
ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF
Corvalan, et al.
Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 52

1.17 H 1	K	T	V	SN	60
1.24 H 1	R	S	D	SN	60
1.38 H 1	R	T	I	ND	60
		[CDR1]		[CDR2]	
1.17 H 61	I		DQG -RYAGY	D	119
1.24 H 61	I		DQG -SYGYV	D	119
1.38 H 61	V		GYD DSSDYL	Y	120
			[CDR3]		
1.17 H 120	126				
1.24 H 120	126				
1.38 H 121	127				



10041860 051302
ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF
Corvalan, et al.
Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 53

1.23 H 1		E S	60
1.25 H 1		R	60
1.29 H 1		S	60
1.39 H 1	T	R	60
1.51 H 1		S	AK 60
		[CDR1]	[CDR2]
1.23 H 61		VS YYVSG---S NV Y	117
1.25 H 61		GS YYGSE---T NV Y	117
1.29 H 61	A	VDVGATIGGYYY HGM V	120
1.39 H 61		GS YYNSG---S NV Y	117
1.51 H 61		YD VWRNY---R TGW P	117
		[CDR3]	
1.23 H 118		126	
1.25 H 118		126	
1.29 H 121	T	129	
1.39 H 118		126	
1.51 H 118		126	



FIGURE 54

1.49 L 1	H	L	S 60
1.11 L 1	Q	Q	N 60
1.29 L 1	H	Q	N 60
	[CDR1]		[CDR2]
1.49 L 61	E	T TIT-- Q RL 111	
1.11 L 61	E	A TLT-- G KV 111	
1.29 L 61	D	A SLMCS Q KL 113	
		[CDR3]	



ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF

Corvalan, et al.

Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 55

1.45 L 1
1.33 L 1
1.38 L 1

N	D	K	L	60
T	Y	K	S	60
T	Y	N	S	60
[CDR1]		[CDR2]		

1.45 L 61
1.33 L 61
1.38 L 61

T	T	Y	F	P	K	D	107
T	T	Y	L	G	K	E	107
S	A	C	W	Q	T	E	107
	[CDR3]						



10041860 081302
ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF
Corvalan, et al.
Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 56

6.4 L 1
1.51 L 1

[CDR1]

AT S 60
GA N 60

[CDR2]

6.4 L 61
1.51 L 61

PCS Q LE 108
LFT P VD 108
[CDR3]



ANTIBODIES DIRECTED TO PDGFD AND USES THEREOF
Corvalan, et al.
Appl. No.: 10/041,860 Atty Docket: ABGENIX.051A

FIGURE 57

1.19	L	1
1.18	L	1
1.16	L	1
1.23	L	1
1.25	L	1
1.39	L	1
1.17	L	1
1.24	L	1
1.46	L	1

F

I

R

[CDR1]

[CDR2]

F

P

1.19	L	61
1.18	L	61
1.16	L	61
1.23	L	61
1.25	L	61
1.39	L	61
1.17	L	61
1.24	L	61
1.46	L	61

D

F

D CS Q L R 107

F P D 107

L G 107

W Q 107

W Q 107

W Q 107

L G 107

W Q 107

SG P Q 107

[CDR3]